Permeability and electrolysis of ablation for extracellular matrix retention
By applying an electric field in the tissue, the cell membrane permeation and electrolysis are achieved, and the combination of reversible electroporation and electrolytic products is combined, the problem of damaging the extracellular matrix during the ablation process in the prior art is solved, and efficient tissue regeneration and ablation accuracy is achieved.
Patent Information
- Application Number
- CN202380035493.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-22
- Filing Date
- 2023-04-21
- Publication Date
- 2024-12-03
AI Technical Summary
Existing minimally invasive tissue ablation techniques can damage all molecules targeting the tissue during the ablation process, resulting in inflammation, coagulated necrosis, scarring and fibrotic tissue formation, hindering tissue regeneration and engineering.
By applying an electric field in the tissue to achieve permeation and electrolysis of the cell membrane, permeated cells are ablated while maintaining the integrity of the extracellular matrix, using the combined effects of reversible electroporation and electrolytic products to accurately control the ablation depth and tissue regeneration.
It realizes the preservation of extracellular matrix in ablated tissue, promotes tissue regeneration, avoids the formation of scars and fibrotic tissues, and improves the ablation accuracy and regeneration ability.
Smart Images

Figure CN119072278A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application Serial No. 63 / 333,948, filed on April 22, 2022, which is incorporated herein by reference in its entirety for any purpose. Technical Field
[0003] The present disclosure relates generally to the field of tissue regeneration. Examples of using cell permeabilization and electrolysis to ablate cells while retaining a decellularized extracellular matrix to allow for tissue regeneration and tissue engineering are described. Background Art
[0004] Tissue within the body can be treated using excision and removal during surgery or medical procedures. In minimally invasive tissue ablation, target tissue can be treated within the body (e.g., in situ) using procedures that involve no excision or require minimal excision. Some examples of minimally invasive tissue ablation techniques include electrolytic ablation, cryosurgery, chemical ablation (e.g., alcohol injection), and thermal ablation (e.g., radiofrequency, microwave).
[0005] Tissue engineering and regenerative medicine are relatively new areas of research in medicine and surgery. Regenerative surgery typically involves ablating target cells in the area being treated and then allowing or promoting the growth of the desired cells in the treated area using an extracellular scaffold that remains intact through programmed elimination of the treated cells by the immune system.
[0006] In minimally invasive tissue ablation using cryosurgery or thermal ablation, the immune system clears the ablated tissue. However, because the ablation techniques of the prior art indiscriminately affect all molecules of the treated tissue, including cell contents and extracellular matrix, normal tissue regeneration required for tissue engineering and / or regenerative medicine does not occur, but scar tissue replaces the ablated tissue within six to eight weeks. For example, after cryosurgery and thermal ablation, there is initially a lot of inflammation and coagulative necrosis. This damage ultimately leads to the formation of scars, ulcers, necrosis, and fibrotic tissue, which remain for several weeks after surgery, and scar tissue and fibrosis may be permanent in these patients. The prior art minimally invasive tissue ablation process using high temperatures for ablation (e.g., via RF energy) and freezing also produces scars, ulcers, necrosis, and fibrotic tissue. Summary of the invention
[0007] Examples of methods are described herein. An example method may include positioning at least one electrode proximate to tissue of a patient, applying an electric field to at least a portion of the tissue of the patient using the at least one electrode, the electric field configured to permeabilize cell membranes in a targeted tissue of the patient, thereby producing permeabilized cells, wherein the permeabilized cells are within a targeted ablation zone, and performing electrolysis to produce electrolysis products in the tissue to ablate the permeabilized cells while leaving an extracellular matrix in the targeted ablation zone intact.
[0008] In some example methods, positioning includes delivering a catheter to a patient, the catheter including at least one electrode.
[0009] In some example methods, applying the electric field includes applying a voltage between at least one electrode and a return electrode positioned proximate to the patient.
[0010] In some example methods, the catheter includes a pair of electrodes, the pair of electrodes includes at least one electrode, and applying the electric field includes applying a voltage between the pair of electrodes.
[0011] In some example methods, the extracellular matrix provides a scaffold for tissue regeneration.
[0012] In some example methods, the electrolysis products do not form scar tissue, fibrotic tissue, coagulative necrosis, ulcers, or combinations thereof.
[0013] In some example methods, applying the electric field includes delivering pulses of 100 V to 1000 V with a capacitance of 50 μF to 100 μF.
[0014] In some example methods, the number of pulses is between 1 and 10.
[0015] In some example methods, the number of pulses is selected based on the ablation depth.
[0016] In some example methods, the electric field generated is between 450 V / cm and 850 V / cm.
[0017] In some example methods, the tissue is the mucosal lining of the small intestine.
[0018] In some example methods, the field strength of the electric field at the interface between the mucosal layer and the submucosal layer is less than the field strength used for irreversible electroporation.
[0019] In some example methods, the electric field at the interface between the mucosal layer and the submucosal layer is less than 850 V / cm.
[0020] In some example methods, the electric field at the interface between the mucosal layer and the submucosal layer is between 450 V / cm and 850 V / cm.
[0021] Some example methods include introducing additional cells into the targeted ablation area by transplantation, migration, or a combination thereof, wherein the additional cells facilitate regeneration.
[0022] Examples of systems are described herein. The example systems include a delivery system having a plurality of electrodes configured to contact a tissue region targeted for ablation, and a controller configured to control an electrical charge applied to the electrodes, the controller configured to induce a voltage to produce permeabilized cells in the tissue region targeted for ablation, and to induce a current to produce an electrolytic product to cause ablation of the permeabilized cells while maintaining an extracellular matrix of at least some of the permeabilized cells intact to allow regeneration of tissue including the permeabilized cells.
[0023] In some example systems, a delivery system includes a catheter, and a distal portion of the catheter includes an expandable member configured to contact a tissue region, the expandable member including a plurality of electrodes.
[0024] In some example systems, a plurality of electrodes extend from a proximal portion to a distal portion of the extendable member.
[0025] In some example systems, the plurality of electrodes is between 12 electrodes and 16 electrodes.
[0026] In some example systems, the plurality of electrodes are circular and generate an electric field between 350 V / cm and 900 V / cm.
[0027] In some example systems, the electrodes have planar surfaces and generate an electric field between 580 V / cm and 930 V / cm.
[0028] Some example systems may further include a power supply that delivers pulses of 100V to 1000V with a capacitance of 50μF to 100μF.
[0029] In some example systems, the controller is configured to select the number of pulses based on the ablation depth.
[0030] Described herein are examples of non-transitory computer-readable storage media that may be encoded with instructions that, when executed by a controller, cause the controller to induce a voltage to produce permeabilized cells in a tissue region targeted for ablation, and to induce a current to produce an electrolytic product, thereby causing ablation of the permeabilized cells while maintaining the extracellular matrix of at least some of the permeabilized cells intact to allow regeneration of tissue including the permeabilized cells.
[0031] In some examples, the induced voltage generates an electric field between 350 V / cm and 930 V / cm.
[0032] In some examples, the controller delivers 1 to 10 pulses between 100V and 1000V with a capacitance between 50μF and 100μF.
[0033] In some examples, the instructions further cause the controller to select the number of pulses based on the ablation depth. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] The above and other features of the present disclosure will become more apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. Understanding that these drawings depict only several examples in accordance with the present disclosure and are therefore not to be considered limiting in scope, the present disclosure will be described with additional specificity and detail through the use of the accompanying drawings, in which:
[0035] Figure 1 is a schematic diagram of an electroporation system according to examples described herein.
[0036] Figure 2A A catheter having an array of parallel electrodes arranged in sequential polarity pairs (+, -, +, - . . . ) is shown, the catheter being depicted in an unexpanded configuration according to examples described herein.
[0037] Figure 2B Shown in extended configuration Figure 2A of the catheter.
[0038] Figure 3 A catheter according to one example described herein is shown.
[0039] Figure 4 is a schematic diagram of a system arranged according to one example described herein.
[0040] Figure 5A is a schematic diagram of anatomical structures arranged according to examples described herein.
[0041] Figure 5B is a schematic diagram of anatomical structures arranged according to examples described herein.
[0042] Figure 6 is a schematic cross-sectional view of the small intestine according to an example described herein, wherein Figure 2B The catheter is deployed in the small intestinal lumen in an expanded configuration.
[0043] Fig. 7A is a schematic diagram of a medical procedure for inserting a catheter or system according to examples described herein.
[0044] Figure 7B is a schematic diagram of a medical procedure for inserting a catheter or other system according to examples described herein.
[0045] Figure 8 is a cross-section of the ablation site in a porcine small intestine after ablation using the examples described herein.
[0046] Fig. 9 is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0047] Fig.10 is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0048] Fig.11 is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0049] Fig.12 is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0050] Fig.13 is a cross-section of a porcine small intestine ablation site using the examples described herein.
[0051] Fig.14A is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0052] Fig. 14B yes Fig.14A Magnified image of .
[0053] Fig.15A is a cross section of a control sample of pig intestine.
[0054] Fig. 15B is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0055] Fig.16A is a cross section of a control sample of porcine intestine.
[0056] Fig. 16B is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0057] Fig.17A is a cross-section of the ablation site in a porcine small intestine after ablation using the examples described herein.
[0058] Fig. 17B is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0059] Fig.18A is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0060] Fig.18B yes Fig.18A Magnified image of .
[0061] Fig.18C yes Fig.18B Magnified image of .
[0062] Fig.19A is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0063] Fig.19B is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0064] Fig.19C is a cross-section of the ablation site of the porcine small intestine after ablation using the examples described herein.
[0065] Fig.19D is a cross section of a control sample of porcine intestine.
[0066] Fig.19E Figure 2 is a cross-section of the ablation site in porcine small intestine 24 hours after ablation using the example described in this article.
[0067] Fig.19F is a cross-section of the ablation site of porcine small intestine 72 hours after ablation using the examples described herein.
[0068] Fig. 20A is a cross-section of the ablation site of porcine small intestine eight days after ablation using the examples described herein.
[0069] Fig. 20B is a cross-section of the ablation site of porcine small intestine eight days after ablation using the examples described herein.
[0070] Fig. 20C is a cross-section of the ablation site of porcine small intestine eight days after ablation using the examples described herein.
[0071] Fig.21 is a schematic cross-section of the duodenum illustrating an example system during operation according to the example arrangements described herein.
[0072] Figure 22A-22C is a schematic diagram of cells being electroporated according to examples described herein.
[0073] Fig.23 is an illustration of a manipulator system according to examples described herein.
[0074] Fig.24A An instrument system according to examples described herein is shown.
[0075] Fig. 24B Shows Fig.24A The distal portion of the instrument system, and extended examples of the instrument according to the examples described herein.
[0076] Fig.25 is a perspective view of a manipulator system according to examples described herein.
[0077] Fig.26 is a schematic diagram of a manipulator system according to examples described herein.
[0078] Fig. 27 is a schematic diagram of electric field amplitudes that can be used in an example system described herein.
[0079] Fig.28A A formulation of an equation representing the electric field generated by electrodes having a space charge density in an example of a system described herein is shown.
[0080] Fig.28B A formula is shown representing an equation for the electric field associated with the potential field in an example of the system described herein.
[0081] Fig.28C A formula is shown for an equation representing the electric displacement field produced by the electrodes in an example of the system described herein.
[0082] Fig.28D The formula representing the relationship between the electric displacement field and the space charge density in the example system described in this article is shown.
[0083] Fig.29 is a table listing the relationship between the number of electrodes, electrode type, and electric field range used in the system examples described in this article.
[0084] Fig. 30A A formula representing the potential equation around a cylindrical conduit and an outer surface ground pad in an example system described herein is shown.
[0085] Fig. 30B The formula for the field equation that represents the relationship between electric potential and radius in an example system described herein is shown.
[0086] Fig. 30C A formula is shown representing an equation for the electric potential used to calculate the relationship between the electric displacement field and the space charge density in an example of the system described herein.
[0087] Figure 31A-Figure 31F A formula representing the equation for determining the electric field used in the example system described herein is shown.
[0088] Fig.32 is a schematic diagram of the electrolysis-electroporation electrode array used in the example system described in this article.
[0089] Fig.33 is a table showing the relationship between treatment sites, experimental conditions, and results in an example of the system described herein.
[0090] Fig.34A and Fig.34Bis a diagram showing the relationship between the number of pulses and the average ablation depth in an example of the system described herein.
[0091] Fig.35 is a diagram showing the relationship between the number of pulses and the percentage of circumferential ablation in an example of the system described herein. DETAILED DESCRIPTION
[0092] Certain details are set forth below to provide a full understanding of the embodiments of the present disclosure. However, it will be clear to those skilled in the art that embodiments of the present disclosure may be practiced without these specific details. In addition, the specific embodiments of the present disclosure described herein are provided by way of example and should not be used to limit the scope of the present disclosure to these specific embodiments. In other cases, in order to avoid unnecessarily obscuring the embodiments, known materials, components, processes, controller components, software, circuit systems, timing diagrams and / or anatomical structures are not described or shown in detail.
[0093] The present disclosure describes the combined effect of electroporation and electrolysis, which can allow more effective ablation of tissue and regeneration of tissue after ablation. The present disclosure relates to a device and system for providing cell permeabilization therapy and controlled delivery of electrolysis products to a targeted site in a tissue. A method for minimally invasive regenerative surgery is disclosed, which includes subjecting a target area in a living tissue to a combination of one or more electric fields and electrolysis. The electric field can be generated by applying a voltage and / or current between one or more pairs of electrodes. The electric field can be generated so that it has a size that permeabilizes the cell membrane in the area where ablation is required. The electric field can be generated to produce a certain amount of electrolysis products, the amount of which itself will not cause damage to cells or extracellular matrix. However, when enough electrolysis products are produced in the permeabilized cell area under the parameters described herein, cell death occurs in the area where the field is applied without damaging the extracellular matrix or scaffold.
[0094] Therefore, electroporation of targeted cell membranes can be performed. Electroporation permeabilizes the cell membrane. Reversible electroporation can be used, wherein permeabilization can be stopped after removing the electric field. Cells can survive reversible electroporation, and the holes in the membrane reseal and restore homeostasis. However, in the examples described herein, the electrolysis product can be applied to permeabilized cells and cause cell death of permeabilized cells in the applied electric field. However, the amount of the product produced by electrolysis may keep the extracellular matrix of permeabilized cells intact and cannot cause damage or ablation in the extracellular matrix. Extracellular matrix generally refers to a three-dimensional network of proteins and / or other molecules (such as collagen fibers, proteoglycans and / or proteins such as fibronectin and / or laminin) that provide structure for cells and tissues. Extracellular matrix can also provide additional signals for cell growth and development. Extracellular matrix can be referred to as non-cellular components, but cells in tissues can usually be surrounded. Extracellular matrix can be used as a scaffold for tissue regeneration and / or engineering. For example, cells can be regenerated, grown, transplanted or otherwise cultured on the extracellular matrix. By retaining the extracellular matrix in the cell area otherwise ablated as described herein, cell regeneration and / or tissue engineering can occur in the ablated cell area. In some examples, by retaining the extracellular matrix of the ablated cell, regeneration and / or tissue engineering can be promoted. In other examples, the extracellular matrix can be transplanted from the area of the ablated cell to another area (may be another area of the ablated cell in some examples), so as to allow regeneration and / or tissue engineering in the transplanted area. The extracellular matrix can be used for the regeneration of the transplanted area. Alternatively or additionally, once there is an extracellular matrix, material can be injected into the extracellular matrix to promote regeneration (for example, by injecting pancreatic islets in some examples). Therefore, material can be injected into the extracellular matrix in the area of tissue and / or the area where the extracellular matrix is transplanted using electroporation and electrolysis ablation as described herein.
[0095] Thus, one aspect of the ablation techniques in the present disclosure relates to the use of electrolysis during the ablation process. The electrolysis process refers to an electrochemical reaction occurring at the electrode surface of an electrode in contact with an ionically conductive medium (e.g., an aqueous solution). Electrochemical reactions typically occur due to potential-driven transfer between electrons in the electrode and ions or atoms in the solution. Chemical species produced at the electrode diffuse outward from the electrode in the ionically conductive medium by an electroosmotic diffusion process. In a typical biological material environment, these chemical reactions also cause changes in pH, resulting in acidic regions near the anode and alkaline regions (basic regions) near the cathode, as well as the production of chemicals that are toxic to biological materials. These products and changes in pH diffuse from the electrode into the biological medium. Electrolysis alone (e.g., without cell membrane permeabilization) is a well-known chemical ablation mechanism, and the extent of ablation depends on the nature of the chemical species and their concentration. Because the electrolysis products are produced at the electrode, in order to ablate a large amount of biological material, the electrolysis products must diffuse throughout the target volume. Diffusion is a slow process, and therefore one of the main disadvantages of electrolysis ablation using only electrolysis ablation is that the procedure can take a long time. Electrolysis products and tissue ablation using electrolysis alone may occur over a period of time on the order of tens of minutes to hours. This is because toxic levels of concentration of electrolysis products throughout the target volume will ablate that volume, and mass diffusion is a slow process. In addition, when electrolysis alone is used to ablate tissue, the concentration of electrolysis products and exposure time can lead to scarring, ulceration, coagulative necrosis, and / or fibrosis.
[0096] Electrolysis preferentially utilizes inert electrodes that do not participate in the electrolysis process except as a source or sink of electrons or as a catalyst. When participating non-inert electrodes are used in the process, they can produce ionic metals that may cause systemic damage to the body, such as excess iron or even metal fragments. Electrolysis products may include products that are toxic to cells. For example, a large number of protons H+ can produce a non-physiological acidic environment diffused from the anode, and a large number of OH- can produce a non-physiological alkaline environment diffused from the cathode. Permeabilized cells exposed to non-physiological pH values may die because the homeostasis of the cell is disrupted and the normal cellular chemical pathways are also disrupted. Electrolysis products can combine and produce chemicals that are toxic to cells, such as hypochlorous acid or hydrochloric acid, and their effects may depend in part on the pH of the area in which they are formed. For example, passing an electric current through a saline solution (NaCl and H2O) with a pH between 3 and 5 may produce highly toxic hypochlorous acid (HOCl). Electrolysis products affect biological substances through the chemical reactions in which they participate, and the degree of influence is a function of their concentration and exposure time. High concentrations and long exposure to electrolysis products can affect all biomolecules in the targeted tissue, which has an undesirable effect on tissue regeneration applications. However, wisely delivering electrolysis products at a lower concentration in a shorter time at a level that cannot affect all biomolecules in the treated tissue volume and can only affect the cells whose membranes are temporarily or permanently permeabilized by diffusing into the cells and affecting the intracellular homeostasis may cause cell death without affecting the extracellular matrix. For example, a typical method of tissue ablation by electrolysis alone can utilize 30-100 coulombs of charge transport per centimeter diameter of the targeted tissue, typically delivering 40mA for 90 minutes. As can be seen from the examples in this article, for regenerative electrolytic electroporation ablation, an exponential decay current with a decay amplitude can be used, and the decay time is much shorter-in one example, the delivery peak is 250mA and the duration is less than 2ms. Therefore, the current provided for electrolysis for electrolytic electroporation ablation described herein can be provided using an exponential decay or other decay waveform, and can have a decay amplitude of tens or hundreds of mA. In some examples, the current can be provided on a millisecond time scale. In some examples, multiple pulses (e.g., multiple waveforms) can be used.
[0097] The examples described herein utilize electrolysis products to cause cell death while utilizing electroporation to permeabilize the cell membrane. The electrolysis products used in these examples are sufficient to ablate (e.g., cause cell death) permeabilized cells in a relatively short time frame. However, the concentration and exposure time of the electrolysis products are insufficient to cause cell death of non-permeabilized cells, and therefore do not cause or contribute to the formation of scar tissue. Instead, the electrolysis products in these examples are only used to ablate permeabilized cells while keeping the extracellular scaffold (e.g., extracellular matrix) intact.
[0098] Examples of systems disclosed herein may include electrodes, power supplies, and controllers. The controller may control the charge delivered to the electrodes to induce one or more electric fields. For example, the electrodes may be used to generate a current to produce electrolytic products, and the voltage difference is used to generate an electric field that induces electroporation. The duration and magnitude of the applied charge may determine the dosage of the electrolytic products and the degree of permeabilization of cells in the treatment site. Therefore, the area of cell ablation may be determined by the area in which the cells are exposed to a combination of permeabilization and electrolytic products that cause ablation. However, ablation may leave the extracellular matrix intact in the area of the ablated cells to which the electric field has been applied. The composition of the electrodes may be selected based on the desired product and electroporation effect.
[0099] Examples of the systems and devices described herein may include electrodes for applying electrolysis and electroporation to tissues. Example devices may be used to treat internal tissues. Examples of the systems and methods described herein create an area of ablated tissue in which the extracellular matrix is retained to promote regeneration (including complete regeneration in some examples). Therefore, the method and apparatus may be used for in situ regeneration of new tissues that may replace undesirable cell types with desired cell types or replace undesirable extracellular matrix with desired extracellular matrix. In some examples, examples of systems and methods may be used in conjunction with implantation of cell types in the treated tissue. Example methods and apparatus may also be used to produce an extracellular matrix that is completely or partially free of living cells, which may also be removed from the treatment site, and the remaining non-cellular matrix material may be implanted or transplanted to a different repair site.
[0100] Examples of the systems and methods described herein utilize the combined effects of electroporation and electrolysis, which can allow for more effective ablation of tissues and regeneration of tissues. Electroporation - permeabilization of cell membranes by applying an electric field to the cell membrane - can utilize two different sets of electrical parameters for tissue ablation: electrical parameters for reversible electroporation and electrical parameters for irreversible electroporation. Reversible electroporation is the permeabilization of the cell membrane, which usually stops after the electric field is removed, and the cell survives under the application of the electric field. In irreversible electroporation, the permeabilization of the cell membrane is permanent, resulting in cell death. Therefore, some electrical parameters can produce irreversible electroporation, in which the holes formed in the cell membrane will not reseal after the electric field is removed, and the permeabilization becomes permanent, resulting in the death of the electroporated cells. In some examples, for biological tissues, electric fields below about 1500V / cm to about 200V / cm are considered to produce reversible electroporation, and electric fields above about 1500V / cm are considered to be irreversible electroporation electric fields. In some examples, electric fields below about 1000 V / cm to about 350 V / cm are considered to produce reversible electroporation, and electric fields above about 1000 V / cm are considered to be irreversible electroporation fields. Examples of the systems and methods described herein can generally utilize reversible electroporation, which can avoid the disadvantages of irreversible electroporation. In some examples, these disadvantages may include heating, the complexity of providing such a large electric field, and muscle contraction that may be caused by the electric field.
[0101] Electroporation is usually directed to the cell membrane. Since the procedure mainly affects the cell membrane, the characteristics of the extracellular matrix are retained. However, since the electric field that causes irreversible electroporation is very large, such as 3000V / cm, applying a high voltage to produce an irreversible electroporation electric field may cause partial thermal damage, thereby damaging both the cells and the extracellular matrix in the field. High voltage may also cause the gas layer formed by electrolysis near the electrode to discharge, thereby causing severe muscle contraction or arcing, which may inadvertently affect the tissue in the region. The large electric field used in irreversible electroporation may also cause muscle contraction, requiring muscle paralysis and general anesthesia, thereby extending the procedure case time, and causing the risk of the patient. Reversible electroporation usually utilizes a smaller electric field, usually less than 1500V / cm. Reversible electroporation parameters are usually used in the examples described herein.
[0102] Electrolysis can produce electrolysis products that can be used to ablate permeabilized cells. However, applying a sufficient amount of electrolysis products to non-permeabilized cells in a sufficient time to ablate non-permeabilized cells may produce scars, ulcers, or fibrotic tissue. Scar tissue and fibrosis indicate that the extracellular matrix has been affected, and the ability of cell regeneration and / or tissue engineering occurring in the ablation area may be inhibited. Therefore, the examples described herein provide exposure to electrolysis products at sufficient levels and times to cause cell death of permeabilized cells, but are low enough to keep the extracellular matrix in the permeabilized cell area intact. In addition, the applied electrolysis product level and / or exposure time are not enough to ablate non-permeabilized cells and / or cause the generation of scars, ulcers, or fibrotic tissue.
[0103] For example, tissue engineering generally refers to the combination of cells, scaffolds, and / or growth factors to regenerate tissue or replace damaged or diseased tissue. Regenerative medicine often combines tissue engineering with other strategies, including cell-based therapy, gene therapy, and immunomodulation, to induce tissue / organ regeneration in vivo. In regenerative medicine, it is important that the treated tissue retains its regenerative capacity. The formation of scar tissue may inhibit and / or prevent tissue regeneration.
[0104] Examples of the systems and methods described herein utilize reversible electroporation to permeabilize cells within a targeted ablation region. Fields for generating reversible electroporation and / or other electric fields can be used to produce electrolysis products. Electrolysis products are introduced into the targeted region to cause only ablation of permeabilized cells (e.g., by diffusion through a permeabilized membrane) without affecting non-permeabilized cells and extracellular matrix. The amount, concentration, and intensity of the electrolysis products provided are such that the extracellular matrix in the permeabilized, ablated cell region remains intact, and non-permeabilized cells survive after treatment. The formation of major inflammation, ulcers, and necrosis is avoided, and ultimately scars and / or fibrotic tissues are greatly reduced and / or eliminated. Therefore, tissues can be regenerated on the decellularized extracellular matrix produced by combining cell membrane permeabilization and electrolysis product application.
[0105] It should be understood that although the systems and methods described herein utilize reversible electroporation, localized or incidental areas may occur where, while most tissue is affected by reversible electroporation, conditions are such that irreversible electroporation or even thermal ablation may occur in limited locations of the treated tissue. Typically, examples of the systems and methods described herein utilize primarily reversible electroporation - e.g., more or a majority of ablation occurs through the use of reversible electroporation and exposure to electrolysis products rather than through irreversible electroporation or thermal ablation. Furthermore, in some embodiments, substantially all of the affected tissue is affected by reversible electroporation, while in other embodiments, all of the affected tissue is affected by reversible electroporation.
[0106] Figure 1is a schematic diagram of an electrolysis electroporation electrode system 100 arranged according to examples described herein. In general, examples of systems described herein may include a delivery system and a controller. Figure 1 In the example of FIG. 1 , the system 100 includes a controller 104 and an electrolysis-electroporation electrode catheter 200. Figure 2A and Figure 2B Examples of catheters that can be used to implement catheter 200 are described in further detail. In some examples, controller 104 may include processor 106, computer readable medium 108 (e.g., memory), and other computing system components, such as one or more input devices, output devices, sensors, and / or communication devices. In other examples, additional, fewer, and / or different components may be used. Computer readable medium 108 includes executable instructions for causing electroporation and electrolysis 110 with catheter 200. Computer readable medium 108 may include stored parameters 112 that can be used in the process for causing electroporation and electrolysis, such as electric field strength, voltage and / or current levels, capacitance, waveform shape, number of pulses, and / or exposure duration parameters.
[0107] The controller 104 may be implemented using a computing device. Examples of computing devices include controllers, microcontrollers, computers, servers, medical devices, smartphones, tablet computers, wearable devices, and the like. The computing device may be handheld or may have other uses.
[0108] Controller 104 may include one or more processors, such as processor 106. Any kind or number of processors may be present, including one or more central processing units (CPUs) and / or one or more graphics processing units (GPUs) with any number of cores, controllers, microcontrollers, and / or custom circuitry, such as one or more application specific integrated circuits (ASICs) and / or field programmable gate arrays (FPGAs).
[0109] The controller 104 described herein may include a computer readable medium 108, such as a memory. Any type or kind of memory may be present (e.g., read-only memory (ROM), random access memory (RAM), solid-state drive (SSD), secure digital card (SD card), and the like). Although Figure 1 A single block is depicted as computer readable medium 108, but there may be any number of computer readable medium 108 devices. Computer readable medium 108 may be in communication with processor 106 (eg, electrically connected to processor 106).
[0110] The computer readable medium 108 may store executable instructions for execution by the processor 106, such as executable instructions for causing electroporation and electrolysis 110 with the catheter 200 using the stored parameters 112 for the catheter 200. In this manner, techniques for applying electroporation and electrolysis in tissue may be implemented herein in whole or in part in software.
[0111] The executable instructions may include instructions for controlling the charge delivered to an electrode, such as an electrode 230 of the catheter 200. Thus, the controller 104 may sense a voltage difference across the targeted tissue to generate an electric field that causes cell permeabilization in the targeted tissue region. In the illustrated embodiment, a plurality of electrodes 230 are disposed on a distal portion of the catheter 200. The plurality of electrodes 230 are shown in a cavity or lumen 12 formed by the tissue 10. Although the catheter 200 is shown as being disposed within the cavity 12 of the tissue 10, the catheter 200 may be located on the surface of the tissue 10, inside the tissue 10, and / or near the tissue 10. In addition, although the catheter is shown for positioning electrodes for permeabilization and / or generating electrolytic products, in other embodiments, other delivery systems may be used and / or one or more electrodes may be otherwise positioned near the tissue, such as by contacting the tissue with (one or more) electrodes or using a probe, pad, needle electrode, flexible laparoscopic electrode, or other device coupled to the electrode to bring the electrode near the tissue.
[0112] Typically, the electrodes used in the examples described herein can be used in a monopolar configuration or a bipolar configuration or a combination thereof. Typically, a monopolar configuration may include an active electrode (e.g., an electrode on or in the surgical field) and a return electrode. The return electrode may be placed outside the surgical field, but in some examples, it may be in contact with the patient (e.g., using a pad with an electrode). In this way, one polarity (e.g., the polarity of the active electrode) is in the surgical field. Therefore, a monopolar electrode configuration may include a pair of electrodes-one powered, and one used as a loop. The return electrode may not be provided on the same device as the powered electrode. For example, the return electrode may be provided on a pad placed near the tissue. In a bipolar configuration, current can flow from one electrode in a pair of electrodes to another electrode. Therefore, it can be said that the polarity of the electrodes in the pair of electrodes is opposite. Multiple pairs of electrodes can be used. In a monopolar configuration, multiple active electrodes may exist, and in some examples, current can be passed through a shared return electrode, or in other examples, through a corresponding return electrode. In a bipolar configuration, current can pass through multiple pairs of electrodes. Any number of electrodes may be used, including two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 24, or 32 electrodes. Any electrode configuration may be used. In some examples, a centrally located electrode may serve as an anode, and multiple electrodes may be positioned around the anode to serve as cathodes. A controller, such as Figure 1 The controller 104 can activate one or more selected electrodes to provide the electric field described herein. In some examples, the controller can alternate or otherwise select a pattern of activated electrodes (e.g., sequentially activate electrode pairs) to shape or deliver a specific electric field. In some embodiments, one or more electrodes used to apply electroporation can also be used to produce electrolysis products (e.g., some or all electrodes can be used for both electroporation and electrolysis), while in other embodiments, the electrodes used to apply electroporation can be different from the electrodes used to produce electrolysis products.
[0113] In general, any shape of electrode may be used, including circular, square, rectangular or other shapes. Interdigitated electrodes may be used.
[0114] The controller 104 can also be used to sense current through the tissue, such as between electrodes, to produce electrolysis products. The electrolysis products may cause ablation of permeabilized cells. The electrolysis products may not be sufficient to destroy the extracellular matrix in the permeabilized cell region, so the permeabilized cells can be ablated while maintaining the integrity of the extracellular matrix in the region. The intact extracellular matrix can allow tissue regeneration and tissue engineering.
[0115] System 100 may include power supply 102. Power supply 102 may be coupled to controller 104. Power supply 102 may be implemented using one or more AC power supplies, DC power supplies, batteries, and / or waveform generators. Power supply 102 may power one or more electrodes to generate voltage and / or current, and thereby generate an electric field and / or electrolysis products in the tissue. In some examples, power supply 102 may be implemented using a signal generator, such as an exponential decay wave generator (e.g., Harvard device BTX630); however, the present disclosure is not limited thereto or thereby. In some examples, the signal generator may include a set of capacitors controlled by controller 104 for selection. The signal generator may allow a specific charge (e.g., capacitance) to be selected each time a charge is applied.
[0116] The controller 104 can control the timing, intensity, and duration of the electric field and / or electrolysis products provided by the catheter 200. For example, the controller 104 can be programmed to provide an electronic signal to the catheter 200. The electronic signal can indicate a therapeutic dose, such as a dose of electrolysis products. The electronic signal can control the timing and magnitude of the current generated by the catheter 200 to generate the electric field. This can allow a user to customize the treatment of the tissue 10. In some embodiments, the controller is coupled to the power supply 102. In some embodiments, the power supply 102 can be included in the system 100. In some embodiments, the power supply 102 is integrated with the controller 104.
[0117] Although shown as a separate component coupled to catheter 200, in some embodiments, controller 104 may be integrated into catheter 200. In some embodiments, controller 104 may include programmable circuitry coupled to catheter 200. Controller 104 may be coupled via wire or in wireless communication with catheter 200.
[0118] In some embodiments, the controller 104 can be programmed to provide an electronic signal indicative of the dosage of the electrolysis product and / or the level of permeabilization of the cells. For example, the controller 104 can include such a program, or include one or more processing devices (e.g., processors) coupled to a computer-readable medium 108 that is encoded with executable instructions for causing electroporation and electrolysis 110.
[0119] Examples of voltage, current, duration and / or time constant, electric field strength, capacitance, and / or number of pulses can be calculated and / or determined according to the methods described herein. In some examples, parameters such as Figure 1Parameters 112 of the invention. For example, measurements may be taken at various voltage levels with a particular electrode configuration, and the voltage level, current, pulse pattern, time constant, and other factors that cause reversible electroporation and delivery of electrolytic products leading to cell death of permeabilized cells may be determined. In general, an electric field may be generated in the tissue that may cause reversible electroporation of cells in the target ablation area. Electrolytic products may be generated and diffuse for a period of time to cause ablation of permeabilized cells, but leave the extracellular matrix intact in the region of the ablated cells.
[0120] Examples of parameters that can be used include the delivery of 1 to 10 or more voltage pulses between 100V and 1000V. In some examples, these pulses can be delivered in a system with a capacitance between 1μF and 400μF selected by a signal generator. In some examples, other capacitance values can be used. In some examples, for example, a resistance between 15-20 ohms can be used to deliver the pulses. Other resistances can be used in other examples. In some examples, an electric field of about 1500V / cm to about 0V / cm can be generated in the tissue. The amount of electrolytic products produced can be related to the delivered charge in coulombs. There are several ways to calculate the delivered charge. For example, the charge Q (in coulombs, abbreviated as C) stored in a capacitor is generally equal to the product of the capacitance C (in farads, abbreviated as F) of the capacitor and the voltage V (in volts, abbreviated as V) between its terminals. That is, Q=C·V. The stored charge is generally equal to the product of the current I (in amperes, abbreviated as A) and the time t (in seconds, abbreviated as s). That is, Q = I·t. By defining the capacitance and the voltage across the capacitor, the charge can be defined and the electrolytic properties determined accordingly. When the capacitor discharges, the capacitor produces a current, and the current multiplied by the time must equal the total charge in the capacitor. When the capacitor discharges, the current is not constant, but decays exponentially. Therefore, the time measurement is expressed as an exponentially decaying time constant. The capacitor that controls the time constant is usually obtained from a power source (such as Figure 1 is obtained from a capacitor included in the power supply 102).
[0121] In some embodiments, the time constant (e.g., the exponential decay time constant of the capacitor discharge) can be between 1.7ms and 1.8ms. In some examples, the time constant can be in the range of 50μs to 3ms. In some examples, the time constant can be in the range of 1 microsecond to 1 second, and in some examples in the range of 100 milliseconds to 10 microseconds. The time constant is generally in the range of microseconds to milliseconds. Generally, the parameters described herein for ablating tissue using electroporation and electrolysis techniques can utilize significantly less charge per unit volume of targeted therapeutic tissue compared to ablation using electrolysis alone (in addition, electrolysis alone may cause scarring and / or other tissue regeneration disorders). For example, consider that in the example experiment described herein, 500V can be delivered in an exponential decay waveform over a resistor of about 20 ohms with a time constant of about 2ms. In some examples, the maximum charge delivered over a 20 ohm resistor is 25Ax (0.002) s = 0.05 coulombs. In some experiments, ablation occurred at a depth of 2 mm around a tube with an outer diameter of 3 cm and a length of 3 cm, for example, the total ablation depth volume was 2.7 cm 3 Thus, an example electrolysis application may utilize a ratio of charge to volume treated of approximately 0.18 coulombs / cm 3 In other examples, other ratios or values may be used. In contrast, an example of pure electrolytic ablation (no electroporation) may use 30-50 Coulombs / cm 3 . Therefore, ablating this volume of tissue by electrolysis alone can utilize an order of magnitude exceeding the charge (e.g., 50-200 coulombs) used in the examples described herein. Therefore, examples of the methods and systems described herein can deliver less than 30 coulombs per cubic centimeter for electrolysis, less than 10 coulombs per cubic centimeter in some examples, less than 5 coulombs per cubic centimeter in some examples, less than 1 coulomb per cubic centimeter in some examples, and less than 0.5 coulomb per cubic centimeter in some examples. The lower limit of the time constant is generally related to the time sufficient to ensure that the electrolytic substance (e.g., electrolysis product) permeabilizes the targeted area of the permeabilized cell. The upper limit of the time constant is generally related to the generation of electrolytic substances (e.g., electrolysis products) that can cause ablation by themselves. Therefore, electrolysis should provide a sufficient amount of time to allow the electrolysis product to diffuse through the area of the permeabilized cell. However, the amount of time provided for electrolysis should not be sufficient to produce the electrolysis product, and the electrolysis product itself will cause ablation of the non-permeabilized cells, so the electrolysis product produced using electrolytic electroporation should not be enough to damage the extracellular matrix in the ablated cell area.
[0122] An electric field between 100 V / cm and 3500 V / cm may be generated. In some examples, the electric field may be between 100 V / cm and 1500 V / cm. In some examples, the electric field may be less than 1400 V / cm, less than 1300 V / cm in some examples, less than 1000 V / cm in some examples, less than 800 V / cm in some examples, and less than 600 V / cm in some examples. In some embodiments, the electric field may be between 200 V / cm and 850 V / cm. Other parameters may be used in other examples. These parameters may be stored in the computer readable medium 108 as parameters 112. In some examples, the controller 104 may be used to calculate the parameters 112. In other examples, the parameters may be calculated by another system and may be provided to the controller 104 and / or stored by the controller 104.
[0123] The system 100 may further include one or more sensors (not shown) for measuring pH, electric field strength, and / or other characteristics of the tissue 10. For example, a pH sensor may be provided. In some examples, the pH sensor may be located and / or attached to the delivery system, such as Figure 1 In some examples, the pH sensor can be placed near the electrodes of the delivery system, such as Figure 1Electrode 230. Thus, the pH value near the electrode can be detected. The pH sensor can be coupled to the controller 104 and the detected pH value is provided to the controller. Additionally or alternatively, the pH sensor can be provided at the outer edge of the targeted tissue area. The pH sensor can be coupled to the controller 104 and the detected pH value is provided to the controller 104. Additionally or alternatively, a pH sensor can be provided at a specific location in the tissue to detect the pH at a specific location, such as a location where tissue damage is not desired. The pH sensor can be coupled to the controller 104 and the detected pH value is provided to the controller 104. The controller 104 can use one or more received pH values as an indication of tissue ablation and / or a potentially harmful pH level that may cause or approach tissue damage. The controller 104 can combine pH values in any manner. For example, the controller 104 can obtain the difference between the received pH values (e.g., the pH value near the edge of the targeted tissue area and the pH value near the electrode). The controller 104 can adjust the voltage, current and / or electric field applied to the tissue in response to the pH level or a combination of pH levels. For example, if the pH value at a location where tissue damage is not desired is at or exceeds a threshold for tissue damage, the controller 104 can reduce the magnitude of the electric field or the duration between pulses, or stop applying the electric field. In some examples, if the pH value in an area where tissue ablation is desired is at or exceeds a threshold for tissue ablation, the controller 104 can stop applying current through the electrodes to stop the electrolysis process immediately before and / or after the desired elapsed electrolysis time.
[0124] A resistivity meter can be used to determine the resistance of the target tissue. For example, a resistivity meter can be provided on the delivery system or otherwise coupled to the delivery system. For example, Figure 1 The controller 104 and / or power supply 102 of the system can provide impedance measurements. The impedance measurements can determine the resistivity of the tissue contacted by the electrodes of the system. For example, the controller 104 and / or power supply 102 can provide a nominal amount of current, such as a DC current, through the tissue, and receive a resistivity measurement and / or calculate the resistivity of the tissue. In some examples, the voltage, current, capacitance, and / or electric field applied can be selected, determined, and / or allowed based on the measured resistance of the tissue. In some examples, the number of pulses of the applied voltage can be selected, determined, and / or otherwise used based on the measured tissue resistance. In some examples, the number of pulses can be in the range of 1 to 10, 20, or 30.
[0125] The number of pulses can be selected to provide a specific dose (e.g., surface charge) that can control the ablation depth and / or the circumferential ablation ratio (e.g., the amount of ablation within a specific circumference may increase). For example, the delivered charge of multiple pulses can be calculated. For example, the charge (in coulombs, abbreviated as C) provided by a capacitor for the number of pulses Q is generally equal to the product of the capacitance C of the capacitor (in farads, abbreviated as F), the voltage V at its terminals (in volts, abbreviated as V), and the number of pulses N (in some examples, a natural number from 1 to 10, 20, or 30 or more). That is, Q=C·V·N. By selecting the number of pulses, the ablation depth and / or the circumferential ablation ratio can be controlled. The device described herein can control the number of pulses (e.g., voltage pulses) delivered based on a specific depth and / or circumferential ablation ratio. Typically, the circumferential amount of tissue affected by ablation may increase as the number of applied pulses increases. Despite the increase in ablation, the generation of heat can be reduced and / or avoided by using a combination of reversible electroporation and electrolysis. If only electrolysis is used to achieve ablation, the applied surface charge may be a small fraction of that normally used.
[0126] In some examples, sensors for detecting and / or determining electric field strength may be used. By measuring the potential difference between adjacent equipotential lines and dividing by the distance between them, the electric field strength at any point may be derived. The distance between the lines is measured along the electric field lines perpendicular to the equipotential lines. In some examples, a gauss meter and / or a tesla meter may be used for this purpose.
[0127] During operation, the electrodes may be introduced into close proximity to the tissue. The electrodes may contact the tissue, be implanted into the tissue, or be positioned on, adjacent to, or near the tissue. For example, a catheter including one or more electrodes (such as catheter 200 including electrode 230) may be delivered to the patient so that the electrodes are close to the tissue.
[0128] Any of the various tissues can be treated using the systems and examples described herein. Typically, tissues can be treated in the case where tissue regeneration is required or a type of cell needs to be replaced with another type of cell. Examples include intestines, duodenum, stomach, bladder, uterus, endometrium, bronchial lining, ovaries, colon, rectum, sinuses, ducts, ureters, prostate, skin, muscles, nerves, diaphragms, momentum, kidneys, follicles, brain, lymphatic vessels, blood vessels, breasts, esophagus, lungs, livers, kidneys, lymph nodes, lymph node basins and / or hearts. Typically, any intracavitary structure can be treated using the systems, devices and techniques described herein. Replacing a tissue with another tissue may be in a fibrotic area, where it is necessary to replace fibrotic cells with stem cells that can readjust the area, or when islets are injected into a portion of the liver to produce a new source of insulin. Other tissues can be treated in other examples.
[0129] The electric field can be applied to at least a portion of the tissue using (one or more) electrodes. For example, the controller 104 can apply a voltage to the electrode 230 to apply the electric field. In some examples, a fluid or other substance can be injected into the tissue, contacted with the tissue, or otherwise placed in or around the tissue to help shape the electric field generated in the tissue. For example, a conductive fluid can help shape the field (e.g., by expanding the field). For example, a non-conductive fluid can help shape the field (e.g., by attenuating the field). In some examples, a non-conductive fluid or other substance can be injected or otherwise placed in the tissue to protect areas that do not require ablation. The electric field may not penetrate and / or pass through the non-conductive fluid, so that the electric field does not reach tissue that does not require ablation, or at least there is not enough strength to cause permeabilization or other cellular changes.
[0130] The electric field can be applied to the target anatomical structure via multiple surgical end effectors to provide precise, accurate and repeatable ablation in open, laparoscopic, thoracoscopic and / or robotic-assisted procedures. For gastrointestinal applications, the delivery system (e.g., ablation device) that delivers electrolytic electroporation can be delivered intracavitary via a manual or robotic delivery device through an oral or anal route, or delivered transabdominally via an integrated bipolar instrument, an inserted probe, or via a catheter. For urological applications, the ablation device that delivers electrolytic electroporation can be delivered intracavitary via a manual or robotic delivery device through a transurethral, transperineal, preperitoneal or transabdominal route, using an integrated bipolar instrument, an inserted probe, or via a catheter. For gynecological applications, the ablation device that delivers electrolytic electroporation can be delivered intracavitary via a manual or robotic delivery device through a transvaginal, transperineal or transabdominal approach, using an integrated bipolar instrument, an inserted probe, or via a catheter. For hepatobiliary applications, the ablation device for delivering electrolytic electroporation can be delivered intracavitary via a manual or robotic delivery device through a transoral route to reach the ampulla, or enter the liver from the outside via a transgastric wall route or a transabdominal approach using an integrated bipolar instrument, an insertable probe, or via a catheter. For neurovascular applications, the ablation device for delivering electrolytic electroporation can be delivered via a manual or robotic delivery device through an intravascular route or through a keyhole craniotomy, using an integrated bipolar instrument, an insertable probe, or via a catheter. For cardiac applications, the ablation device for delivering electrolytic electroporation can be delivered via a manual or robotic delivery device through an intravascular or transthoracic route, using an integrated bipolar instrument, an insertable probe, or via a catheter. In the case of endobronchial ablation of the lungs to treat chronic obstructive pulmonary disease (such as chronic bronchitis and emphysema), the ablation device for delivering electrolytic electroporation can be delivered intracavitary via a manual or robotic delivery device, via a nasal or transoral approach, using an integrated bipolar instrument, an insertable probe, or via a catheter. Various manual and robotic delivery devices are further described herein.
[0131] The intensity of the electric field in the tissue can cause reversible electroporation in the cell area targeted for ablation. As a result, the cell membranes in the tissue area targeted for ablation can be permeabilized. Figure 1 In the examples of the present invention, the circle depicted around the end of the catheter 200 can indicate a cell area that can be permeabilized according to the electric field applied by the electrode. For example, Example 1 below describes a 30 mm diameter extended electrode configuration with a 0.85 mm depth of field. In some examples, the electric field can be constant over a period of time and / or can be pulsed. The pulses of the electric field can have any of a variety of shapes (e.g., square pulses, triangular pulses, pulsed pulses, and / or exponentially decaying pulses).
[0132] Electrolysis can be performed to produce electrolysis products. For example, electrolysis products can be produced from ions and molecules of an aqueous solution. The aqueous solution can be a solution of natural physiological concentrations found in tissues. The ionic composition of body fluids can be used as an ionically conductive medium to cause electrochemical reactions that form the basis of electrolysis, and / or can be introduced (e.g., injected) into tissues during the methods described herein. The electrolysis products can be produced by using electrodes described herein (such as Figure 1 Electrodes 230) pass current through tissue to generate. Electrolysis products may diffuse in the tissue and may ablate permeabilized cells. The duration of electrolysis and / or the amount of electrolysis products produced can be set herein so that the electrolysis products cause ablation of permeabilized cells but do not cause ablation of non-permeabilized cells. In addition, the duration and / or amount of electrolysis products can be set so that the extracellular matrix of permeabilized cells remains intact, which can promote regeneration of the ablated tissue area.
[0133] The process of applying an electric field to cause permeabilization and electrolysis can be performed by a computing system as described herein (such as Figure 1 The controller 104) is controlled according to executable instructions 110 for causing electroporation and electrolysis.
[0134] In some examples, the electrodes can be moved to other tissue locations (e.g., by advancing and / or retracting catheter 200). In this way, electroporation and electrolysis can be performed at multiple locations in the patient, such as to cover a larger area. In some examples, multiple sets of electrodes can be positioned at multiple corresponding tissue sites so that electroporation and electrolysis can be performed in parallel at each site, thereby reducing and / or eliminating the need to repeat the procedure as the catheter is moved through the patient.
[0135] After ablation using electroporation and electrolysis, the extracellular matrix (e.g., extracellular scaffold) remains intact and tissue regeneration may occur. In some examples, the regeneration of tissue may occur in hours, and / or days, and / or weeks, and / or months. The tissue itself can be brought to the stem cells in the region from the blood circulation, or from the stem cells at the edge of the ablated tissue, or from the residual stem cell regeneration, and regeneration may not require additional intervention. However, in some examples, cells or other components can be introduced into the ablation site. For example, stem cells, organoids, or other desired cells, parts, compounds, or components can be introduced into the ablation site (e.g., using catheter 200 or otherwise injecting or introducing components). Cells or other components can facilitate (e.g., enhance) regeneration and / or regeneration can be directed to a specific cell type or position.
[0136] In some examples, the migration, implantation and / or transplantation of cells can be used to facilitate tissue engineering and / or regeneration. For example, stem cells may remain at the edge of the ablated tissue area. Stem cells in the edge area can migrate to facilitate regeneration. In some examples, cell signaling can be promoted (e.g., in the extracellular matrix), which may facilitate the migration or direction of cell growth.
[0137] There are several ways to regenerate the desired tissue to replace some or all of the cells ablated with electrolytic electroporation. The process may depend on the action of the immune system and the normal regeneration of cells in the targeted area. In some examples, the immune system can remove cells within 24 hours after applying electrolytic electroporation, and the cells begin to regenerate in the ablated area 24 hours later. Natural regeneration can occur in a variety of ways. First, in some examples, cells in a given treated area can be ablated to keep stem cells alive in this way. For example, resident stem cells in mucosal crypts can be exempted from ablation. The second method, which is particularly effective for areas such as the intestine, is that resident stem cells from the edge of the ablated area proliferate to the ablated area along the intact extracellular matrix. The third method is to ensure that the blood circulation of the treated area remains intact, and circulating stem cells reach the treated area through the blood circulation. This mode is particularly effective in high vascular tissues (such as the liver). In the examples described herein, any or all of these mechanisms can be used to regenerate tissue. Differentiation of cells (such as hepatocytes) also contributes to regeneration. The intact extracellular matrix may be the core of the regeneration process. Stem cells have great prospects in treating many diseases by promoting endogenous cell repair or by direct cell transplantation. The extracellular matrix (ECM) is a component that mediates the fate of stem cells.
[0138] Ideal regeneration can be achieved by natural processes, in which the system mechanism repopulates the decellularized extracellular matrix. However, there are other methods that can repopulate the extracellular matrix with cells different from the original cells at the position (e.g., in the intestine). For example, if the previous cells suffer from genetic malformations, genetically engineered cells can be injected into the decellularized mucosa that does not carry genetic defects (e.g., injected into the ablation cell area) to replace the original cells. For example, in the liver, in the fibrotic area, in some examples, liver stem cells can be injected into the decellularized fibrotic area (e.g., ablation area) to reorganize the extracellular matrix. Other examples include pancreatic islets. A common method for treating type I diabetes is to inject exogenous islets through the portal vein, hoping that they can be implanted in the liver. A preferred method is to inject islets into the decellularized volume of the liver. One aspect of this tissue regeneration mode is the timeline between cell ablation, the removal of ablation cells by the immune system, and the natural regeneration process. In this treatment mode, it is preferred to inject exogenous cells in the time interval between the time when the immune system has removed the cells to avoid active immune system attacks on implanted cells, and to inject at the beginning of normal regeneration to avoid competition between two types of cells. In the examples described herein, the time window may be between 6 hours after ablation and 24 hours after ablation, preferably about 25 hours after ablation. The time window may be tissue specific and may be adjusted according to a particular application.
[0139] Fig.21 is a schematic cross-section of the duodenum illustrating an example system during operation according to the example arrangements described herein. Fig.21 The invention includes an expandable member 2108 disposed in the duodenum 2114. For example, Fig.21In the embodiment of the present invention, the expandable member 2108 can be set in the fourth part of the duodenum 2114. The fourth part 2114 of the duodenum is generally the ascending part of the duodenum, generally located at the vertebral level L-3, and can pass directly from the top of the aorta or slightly to the left. However, the expandable member 2108 can be alternatively positioned in other parts of the duodenum 2114. The expandable member 2108 can include an electrode array 2110. The expansion of the expandable member 2108 can cause the expandable member 2108 to contact the inner lining of the intestine, which may be completely and / or partially diseased. For example, the mucosal lining 2112 can be targeted for ablation. Note that various tissue structures are adjacent to and / or close to the targeted tissue, such as the pancreas 2104, the bile duct 2102, the superior mesenteric artery and vein 2106, and / or the ampulla 2116 of Vaster. The examples described herein can allow for ablation and / or regeneration of the mucosal lining 2112 while minimizing and / or avoiding effects on other structures (such as blood vessels, catheters, and / or nerves). For example, in some embodiments, electrolytic electroporation can be applied to the mucosal lining 2112 of the duodenum 2114 without the need to protect sensitive structures (such as blood vessels, catheters, and / or nerves) from ablation. The expandable member 2108 and / or electrode array 2110 can be used to implement and / or be implemented by any of the expandable member and / or electrode structures described herein, including those described with reference to Figure 1-Figure 4 those shown and / or described.
[0140] Figure 22A-22C is a schematic diagram of a cell being electroporated according to the examples described herein. Fig.22A , cell 2202 is exposed to an electric field, as shown in part by electric field lines 2204. For example, cell 2202 may be Fig.21 When exposed to the electric field, the cell 2202 may undergo electroporation during the exponential decay time of the voltage and / or current waveform used to generate the electric field. For example, a hole or other perforation may be formed in the cell membrane of the cell 2202. Fig. 22B In FIG. 2 , the cell membrane of cell 2202 is shown as having holes 2208, indicating that the membrane has been partially and / or completely permeabilized. The application of the electric field can continue, including as shown by electric field lines 2204. Electrolysis products such as Fig. 22B As shown in the figure, particles 2210 are shown around the cell 2202. Fig. 22C, a cell 2202 is depicted wherein an electrolytic product diffuses into the cell 2202, for example, through a permeabilized cell membrane. The extracellular matrix 2206 may not be affected by the electrolytic product, electroporation, and / or application of an electric field. Thus, upon exposure to the electrolytic product diffused into the cell membrane of the cell 2202, the cell 2202 may die. The dead cells may be referred to as "ghost cells" and may be ablated. The dead cells may be absorbed by the body and / or surrounding tissues (e.g., using an immune response). In some examples, the dead cells may be sloughed off from the submucosal layer and removed. Thus, Fig.21 The mucosal lining 2112 can be ablated. After ablation, regeneration can occur, thereby providing a healthy regenerated mucosal lining 2112.
[0141] Fig. 27 is a schematic diagram of electric field amplitudes that can be used with examples of the systems described herein. Fig. 27 The electric field waveforms shown in FIG. 1 may be used by ablation devices described herein, such as Figure 1 For example, Fig. 27 The electric field shown can be given by Figure 1 The electrode 230 is provided. Typically, Fig. 27 The waveform of can represent the voltage that can be applied by the electrodes described herein. An exponentially decaying waveform can be used. Fig. 27 Three examples of such waveforms with different time constants are shown in . The time constant refers to the time it takes for the exponential decay to cause the level to decrease to a small fraction of the peak field applied. Fig. 27 In the example of FIG. 1 , the peak electric field strength is shown as E0, and the time constant is measured when the field strength drops to 0.37E0. The peak electric field strength (eg, the peak voltage applied) can be determined, for example, by Figure 1 In some examples, the peak electric field strength (eg, the peak voltage to be applied) may be stored in Figure 1 The time constants used in the systems described herein can typically be on the order of microseconds to milliseconds and / or seconds. The initial portion of the waveform is typically a higher field strength and is typically when cells are likely to be electroporated, such as Fig.22A As the intensity continues to decay, the second part of the waveform is usually when electrolysis products are formed, such as Fig. 22B shown. Fig. 27 Three waveforms are shown in FIG. Each may be referred to as a pulse as described herein. The three waveforms differ in their time constants (eg, their decay rates).
[0142] Figure 2A and Figure 2BAn example of a catheter 200 according to the examples described herein is shown. According to an embodiment of the present disclosure, the catheter 200 can provide electrolysis and electroporation therapy. The catheter 200 includes a slender member 210 having a distal end 212 and a proximal end (not shown). The slender member 210 can be a tubular member including a lumen 214 extending from the proximal end to the distal end 212. In some embodiments, the lumen 214 can extend from the proximal end to a position proximal to the distal end 212. The distal end 212 can have a closed end. The length of the slender member can be at least 85 cm, preferably 1.8 m in length, and the diameter of the slender member can be about 7 mm, preferably with a maximum outer diameter of 5 mm, to allow introduction through the working channel of an endoscope.
[0143] The catheter 200 may include an expandable member 220. In the illustrated embodiment, the expandable member 220 is a balloon. Other expandable members may be used in other examples, such as meshes and the like. The expandable member 220 may be expanded in a variety of different ways. In some embodiments, the expandable member 220 may be inflated with a fluid, such as air, saline, a radiopaque solution, and the like. The fluid may be introduced into the expandable member 220 through the lumen 214 of the elongated member 210. Figure 2A The expansion member 220 is shown in an unexpanded configuration, and Figure 2B The expansion member 220 is shown in an expanded configuration. In the unexpanded configuration, the expandable member 220 can have a length of 4 cm and can expand to a diameter between 1 cm and 3 cm. However, the length and expandable diameter of the expandable member 220 can vary depending on the tissue on which the catheter 200 is used. In other examples, the expandable member 220 can be expanded in other ways (e.g., rolled, unfolded, pushed).
[0144] The catheter 200 may further include a plurality of electrodes 230. The plurality of electrodes 230 may be used to provide electrolysis and electroporation to the targeted tissue simultaneously. Although a plurality of electrodes 230 are shown, in some examples, multiple pairs of electrodes may be used. In some examples, an electrode may be disposed on the catheter 200 and may be used in conjunction with a return electrode (e.g., in a monopolar configuration). In some examples, the electrodes may be positioned and / or spaced apart to create and / or promote a uniform electric field. In some examples, one or more electrodes may be physically connected to one or more other electrodes (e.g., using a mesh or other portion of a connecting material) to form a fixed spacing between the electrodes.
[0145] In the illustrated embodiment, the plurality of electrodes 230 extend in the longitudinal direction from at least the proximal portion 222 of the expandable member 220 to the distal portion 224. The number of electrodes 230 can be between 2 electrodes and 30 electrodes, and in some examples can be between 12 electrodes and 16 electrodes. Other numbers of electrodes can also be used. In some embodiments, the plurality of electrodes 230 have a circular cross-section. In some embodiments, the plurality of electrodes can have a flat surface. In some examples, needle electrodes (e.g., electrodes that fully and / or partially penetrate tissue) can be used. The plurality of electrodes 230 can alternate between anode and cathode arrangements. The anodes and cathodes of the plurality of electrodes 230 can be separated by a dielectric at any point where they intersect. In some embodiments, the anodes and cathodes can cross each other so that in a compressed state, the design of the electrodes can resemble a Chinese finger trap.
[0146] The anode and cathode can be made of any conductive material, such as stainless steel, titanium, graphene, graphite, and the like. In general, the electrode material can be selected so that the electrode material does not actively participate in the electrolysis product and / or leave material residue. For example, the electrode material can be selected to minimize the transfer of ions from the electrode material to the target tissue. For example, steel may not be preferred. Titanium and gold may participate in the electrolysis process to some extent; however, they may not produce toxic residues and can be used in some examples. In some examples, titanium can be used and may be preferred. In some examples, stainless steel can be used. In some examples, two separate metals, such as zinc and aluminum, can be used, which can generate current when they are very close, thereby possibly producing electrolysis products. In some examples, the diameter of the plurality of electrodes 230 can be about 0.88 mm, but other sizes can also be used. When in an unexpanded configuration, in some examples, the spacing between adjacent electrodes 230 can be between 0.05 mm and 0.005 mm, but other spacings can also be used. In an extended configuration, in some examples, the spacing between adjacent electrodes 230 can be about 5 mm, but other spacings can also be used.
[0147] The distal portion 234 of each electrode 230 can be fixed to the distal end 212 of the elongated member 210 or the distal portion 224 of the expandable member 220. The proximal portion 232 of each electrode 230 can be coupled to a ring 236 proximal to the expandable member 220. When the expandable member 220 is inflated or otherwise expanded, the plurality of electrodes 230 are disposed on the outer surface 226 of the expandable member 220. In some examples, the ring 236 can move to accommodate the expansion. In some examples, the ring 236 can remain stationary.
[0148] Multiple electrodes 230 can be attached to two or more wires extending along the elongated member 210, which provide electrical signals, such as voltage and / or current, to the multiple electrodes 230. These two wires extend downward along the length of the elongated member 210 to the controller 104 and / or the power supply 102 generator, which can be outside the body. Once the expandable member 220 is positioned in place and expanded to an expandable configuration (the expandable member 220 compresses the stent to the gastrointestinal wall), current will flow through the electrodes, thereby generating an electrolysis and electroporation field. The applied electric field can be between 100V / cm and 1500V / cm. Then, the expandable member 220 can be reduced. In some embodiments, the expandable member 220 can be removed, and the multiple electrodes 230 can be left in place to continue to produce electrolytic substances (for example, if the multiple electrodes are made of self-powered materials), to inhibit the regeneration of tissue 10 or other anatomical structures in an extended period from a few days to a few years. For example, one or more electrodes can be made of piezoelectric and / or thermoelectric materials, which can generate electricity over time. In some examples, a power source can be placed in the tissue, such as a battery. In some examples, a microbattery can be used, which can include one or more electrodes described herein or other electrodes. In some examples, the microbattery can be charged using microcurrents in the tissue (e.g., body microcurrents). For example, a stent with such a microbattery can be used.
[0149] Figure 3 A catheter 300 according to an example described herein is shown. According to an embodiment of the present disclosure, the catheter 300 can provide electrolysis and electroporation therapy. The catheter 300 includes an elongated member 310 having a distal portion 312 and a proximal portion (not shown). The elongated member 310 can be a tubular member including a lumen 314 extending from the proximal portion (not shown) to the distal portion 312. The distal portion 312 can have a closed end. The catheter 300 can be introduced into a targeted tissue for ablation, delivery of electrolysis products, and regeneration, such as the lumen 12 of a patient's small intestinal tissue 10.
[0150] The catheter 300 may further include a plurality of electrodes 330 disposed at the distal portion 312 of the elongated member 310. The plurality of electrodes 330 may be used to provide electrolysis and electroporation simultaneously. The plurality of electrodes 330 may include a distal electrode 332 and a proximal electrode 334. Each electrode 332, 334 may be wrapped around the elongated member 310.
[0151] The distal portion 312 of the elongated member 310 may include (e.g., may define) a plurality of apertures 316. The plurality of apertures 316 may be disposed between the distal electrode 332 and the proximal electrode 334. The conductive gel 318 may be advanced through the lumen 314 from the proximal portion of the elongated member 310 to the distal portion 312 of the elongated member 310 to exit the elongated member 310 through the plurality of apertures 316. For example, the conductive gel 318 may fill the lumen 12 up to the tissue 10 of the small intestine to help shape the electric field and / or deliver electrolysis products to the targeted tissue.
[0152] Figure 4 A schematic diagram of a system 400 according to one embodiment of the present disclosure is shown. The system 400 may include a catheter 410 having an electrode 430 disposed at a distal portion of the catheter 410. The system 400 may also include a ground pad 440 in operative communication with the electrode 430 of the catheter 410. Thus, one or more ground electrodes (e.g., a ground pad) may be used as some or all of the electrodes described herein. Typically, the ground electrode may be coupled to a reference voltage (e.g., ground). Although Figure 1 is not shown, but note that a ground electrode may also be present in the reference Figure 1 In the described system, for example, the ground electrode is placed on or near the patient. As described herein, the ground electrode can facilitate the generation of an electric field in the tissue.
[0153] therefore, Figure 4 The system can be used to implement Figure 1 For example, catheter 200 or catheter 300 can be used to implement Figure 4 The catheter 410 and / or can be implemented by it. Figure 1 One or more ground electrodes may be provided in the system, which may be further coupled to catheter 200 or catheter 300 and / or power source 102 or controller 104.
[0154] In some embodiments, an ablation device that delivers electrolytic electroporation can be delivered via a computer-assisted, remotely operated manipulator system, sometimes referred to as a robot-assisted system or a robotic system. The manipulator system includes one or more manipulators that, when coupled to the manipulator, can be operated with the aid of an electronic controller (e.g., a computer) to move and control the functions of one or more instruments.
[0155] Fig.23 One embodiment of a computer-assisted manipulator system for use with the ablation devices described herein is shown. The manipulator system may be used, for example, for a surgical, diagnostic, therapeutic, biopsy, or non-medical procedure (collectively referred to herein as a "procedure"), generally indicated by reference numeral 2300. Fig.23As shown, the manipulator system 2300 generally includes a remotely operated manipulator assembly 2302 for operating a medical device system 2304 to perform various procedures, such as performing a medical procedure on a patient P. The medical device system 2304 may include one or more steerable instruments and / or one or more passive instruments. One or more instruments of the medical device system 2304 may be configured to be positioned within a working channel of one or more other instruments of the medical device system 2304. In some examples, one or more surgical instruments or tools may be positioned within one or more working channels of an instrument such as a catheter or endoscope of the medical device system 2304. The manipulator assembly 2302 is mounted on or near a patient support table T, which may be located in an operating room or other medical environment. An operator input system 2306 allows an operator (e.g., a clinician, surgeon, or other personnel) S to view the intervention site and control the manipulator assembly 2302. Fig.23 2304, and an operator input system 2306. However, it should be understood that various teleoperation systems may have multiple manipulator assemblies, medical instrument systems (each including one or more medical instruments), operator input systems, or combinations thereof.
[0156] The operator input system 2306 can be located at a user control system that is typically located in the same room as the patient support table T. However, it should be understood that the operator S can be located in a different room or a completely different building, or geographically remote from the patient P. The operator input system 2306 typically includes one or more control devices for controlling the manipulator assembly 2302. The control device can include any number of various input devices or sensors, such as a joystick, a trackball, a data glove, a trigger gun, a hand controller, an eye tracking device, a voice recognition device, a body motion or presence sensor, or the like. In some embodiments, the control device will have the same degrees of freedom as one or more associated medical device systems (such as medical device system 2304) to provide the operator with telepresence, or provide a sense that the control device is integrated with the medical device system so that the operator has a sufficiently strong sense of direct control of the medical device system. In other embodiments, the control device can have more, less, or different degrees of freedom than one or more associated medical device systems (such as medical device system 2304) and still provide telepresence for the operator. In some embodiments, the control device is a manual input device that moves with six degrees of freedom and may also include an actuatable handle for actuating the instrument (e.g., for closing a jaw, applying an electrical potential to an electrode, delivering a drug therapy, or the like).
[0157] The teleoperated manipulator assembly 2302 supports the medical device system 2304 and may include one or more non-servo and / or servo-controlled linkages (e.g., one or more linkages that can be manually or automatically positioned and locked in place, generally referred to as setup structures) and kinematic structures of the teleoperated manipulator. The teleoperated manipulator assembly 2302 includes a plurality of actuators or motors that drive inputs on one or more instruments of the medical device system 2304 in response to commands from a control system (e.g., control system 2312). The motors include a drive system that, when coupled to the medical device system 2304, can advance the (one or more) instruments of the medical device system 2304 into a natural or surgically created anatomical hole. Other electric drive systems can move the distal end of the (one or more) instruments of the medical device system 2304 in multiple degrees of freedom, which may include three degrees of translational motion (e.g., translational motion along the X, Y, Z Cartesian axes) and three degrees of rotational motion (e.g., rotation around the X, Y, and Z Cartesian axes). In addition, the motor can be used to actuate an articulated end effector of the instrument to grasp tissue in a clamp of a biopsy device or the like. Motor position or velocity sensors, such as resolvers, encoders, potentiometers, and other mechanisms, can provide sensor data describing the rotation and orientation of the motor shaft to the remote operation assembly. This position sensor data can be used to determine the motion of an object manipulated by the motor.
[0158] Manipulator system 2300 also includes a sensor system 2308 having one or more subsystems for receiving information about subcomponents of manipulator system 2300 of an instrument including manipulator assembly 2302. Such subsystems may include at least one of or a combination of: a position / location sensor system (e.g., an electromagnetic (EM) sensor system); a shape sensor system for determining the position, orientation, speed, velocity, pose, and / or shape of at least a portion of an instrument of medical instrument system 2304, such as a flexible steerable body or a rigid instrument body with or without joints; a visualization system for capturing images from a distal end of the instrument; other sensor systems based on various sensor technologies; or a combination thereof.
[0159] In some examples, a visualization system (e.g., Fig.24AThe visualization system 2431) may include a viewing mirror assembly that records concurrent or real-time images of the surgical site and provides the images to an operator (e.g., a clinician or surgeon or other personnel) S. The concurrent images may be, for example, two-dimensional or three-dimensional images captured by an endoscope located within the surgical site. In some embodiments, the visualization system includes an endoscope component that may be integrally or removably coupled to one or more instruments of the medical instrument system 2304. However, in alternative embodiments, a separate endoscope attached to a separate manipulator assembly may be used with the medical instrument system 2304 to image the surgical site. The visualization system may be implemented as hardware, firmware, software, or a combination thereof that interacts with or is executed by one or more computer processors, which may include a processor of the control system 2312. The processor of the control system 2312 may execute instructions including instructions corresponding to the processes disclosed herein.
[0160] The manipulator system 2300 also includes a display system 2310 for displaying images or representations of the surgical site and / or medical instrument system(s) 2304 generated by the subsystems of the sensor system 2308. The display 2310 and operator input system 2306 may be oriented so that the operator may control the medical instrument system 2304 and the operator input system 2306 through the perception of the telepresentation.
[0161] The display system 2310 can also display images of the surgical site and medical instruments (e.g., instruments of the medical instrument system 2304) captured by the visualization system. The display 2310 and the control device can be oriented so that the relative position of the imaging device in the mirror assembly and the medical instrument is similar to the relative position of the operator's eyes and hands, so that the operator can manipulate the medical instrument system 2304 and the hand controls as if viewing the workspace with substantial presence. By presence, it is meant that the presentation of the image is a true perspective image simulating the viewpoint of the operator physically manipulating the medical instrument 2304. Alternatively or additionally, the display 2310 can present images of the surgical site recorded before or during surgery and / or virtual navigation images.
[0162] The manipulator system 2300 also includes a control system 2312. The control system 2312 includes at least one memory and at least one computer processor (not shown), and in some embodiments typically includes multiple processors, which are used to implement control between the medical device system 2304, the operator input system 2306, the sensor system 2308, and the display system 2310. The control system 2312 also includes programmed instructions stored on a non-transitory processor-readable storage medium (e.g., a computer-readable medium storing instructions) to implement some or all of the methods described according to the various aspects disclosed herein, including instructions for providing information to the display system 2310. Although the control system 2312 is Fig.23 2302, another portion of the processing is performed at the operator input system 2306, and so on. Any of a variety of centralized or distributed data processing architectures can be used. Similarly, the programmed instructions can be implemented as multiple separate programs or subroutines, or they can be integrated into many other aspects of the manipulator system described herein. In one embodiment, the control system 2312 supports one or more wired or wireless communication protocols. Wireless communication protocols include examples such as Bluetooth, IrDA (infrared data communication), HomeRF (home radio frequency), IEEE 802.11, DECT (digital enhanced cordless communication), and wireless telemetry.
[0163] In some embodiments, the control system 2312 may include one or more servo controllers that receive force and / or torque feedback from one or more medical devices, such as those of the medical device system 2304. In response to the feedback, the servo controller sends a signal to the operator input system 2306. The servo controller(s) may also send a signal instructing the teleoperation assembly 2302 to move a medical device that extends to an internal surgical or treatment site in the patient's body via an opening in the body. Any suitable conventional or dedicated servo controller may be used. The servo controller may be separate from or integrated with the teleoperation assembly 2302. In some embodiments, the servo controller and teleoperation assembly 2302 are provided as part of a teleoperation arm cart that is configured to be positioned adjacent to the patient's body during a surgical procedure.
[0164] The manipulator system 2300 may further include optional operating and support systems (not shown), such as lighting systems, steering control systems, irrigation systems, suction systems, cautery or energy application systems, other systems or combinations thereof. In alternative embodiments, the manipulator system 2300 may include more than one remotely operated assembly 2302 and / or more than one operator input system 2306. The exact number of remotely operated manipulator assemblies will depend on the surgical procedure and the space limitations within the operating room and other factors. The operator input systems may be juxtaposed, or may be located in separate locations that are geographically close to or far from each other. Multiple operator input systems allow more than one operator to control one or more manipulator assemblies in various combinations.
[0165] Fig.24A A medical instrument system 2400 is shown that can be used as or in a medical instrument system 2304 in an image-guided medical procedure performed with a manipulator system 2300. Alternatively, the medical instrument system 2400 can be used for non-teleoperated exploratory procedures or procedures involving traditional manually operated medical instruments, such as endoscopy.
[0166] The instrument system 2400 includes a flexible steerable body 2402 coupled to a housing 2404. The flexible steerable body 2402 has a proximal end 2417 and a distal or tip portion 2418. In various embodiments, the flexible steerable body 2402 has a size and shape that reaches the target anatomical structure, such as a diameter of 4mm to 25mm. Other flexible steerable body outer diameters can be larger or smaller. The instrument system 2400 can optionally include one or more shape sensors 2422, which are used to determine the position, orientation, speed, rate, posture, shape or other physical characteristics of at least a portion of the flexible steerable body tip at the distal end 2418, along one or more segments 2424 of the flexible steerable body 2402 and / or along the flexible steerable body 2402 that can be positioned in the channel 2421 of the flexible steerable body 2402 (e.g., instrument 2426). The entire length of the flexible steerable body 2402 between the distal end 2418 and the proximal end 2417 can be effectively divided into segments 2424.
[0167] The medical device system 2400 (e.g., the flexible steerable body 2402 and / or the device 2426) can optionally include one or more position sensor systems 2420 and / or shape sensors 2422, which can be provided within the flexible steerable body 2402 or the device 2426 or mounted externally to the flexible steerable body 2402 or the device 2426. The tracking system 2430 can include one or more position sensor systems 2420 and one or more shape sensors 2422 for determining the position, orientation, velocity, posture, and / or shape of the device. The tracking system 2430 can be implemented as hardware, firmware, software, or a combination thereof that interacts with or is otherwise executed by one or more computer processors, which can include a processor of the control system 2312.
[0168] The flexible steerable body 2402 includes one or more channels 2421, which are sized and shaped to accommodate one or more medical devices 2426. Medical devices may include, for example, image capture devices (e.g., endoscopes, such as monoscopic or stereoscopic endoscopes), electrosurgical devices, biopsy instruments, laser ablation fibers, or other surgical, diagnostic, or therapeutic tools. Medical devices may include an end effector having one or more working members, such as a scalpel, a blunt blade, an optical fiber, or an electrode. Other end effectors may include, for example, forceps, grippers, scissors, clip applicators, etc. Examples of electrically activated end effectors include electrosurgical electrodes, transducers, sensors, and the like. One or more channels 2421 may have a diameter of, for example, about 3 mm to 20 mm. In one example, one or more channels 2421 may be configured to accommodate an instrument of about 5 mm and may have a diameter of about 6 mm. The diameter of other channels 2421 may be larger to accommodate larger instruments, such as image capture devices. For example, the flexible steerable body 2402 may include a channel 2421 sized to accommodate a larger instrument, such as an image capture device, and two lumens sized to accommodate a flexible instrument 2426. However, other embodiments may include more or fewer lumens (such as one, two, three, or more lumens).
[0169] In various embodiments, one or more medical devices 2426 can be or include an image capture device including a distal portion having a stereoscopic or monoscopic camera that is processed by the visualization system 2431 for display. The image capture device can include a cable coupled to the camera for transmitting captured image data. Alternatively, the image capture device can be a fiber optic bundle coupled to the visualization system, such as a fiber optic endoscope. The image capture device can be single-spectrum or multi-spectrum, for example, for capturing image data in one or more of the visible, infrared, and / or ultraviolet spectra.
[0170] In some embodiments, the flexible steerable body 2402 may include an image capture device, such as a stereo camera, disposed at or near the distal end 2418 for capturing images (including video images). A plurality of lumens 2421 extending through the flexible steerable body 2402 may provide access for a plurality of instruments 2426 to access a surgical site within the field of view of the image capture device.
[0171] Medical device 2426 can accommodate a cable, linkage mechanism or other actuation control (not shown) extending between the proximal and distal ends of the device to controllably bend the distal end of the device. Flexible steerable body 2402 can also accommodate a cable, linkage mechanism or other manipulation control (not shown) extending between housing 2404 and distal end 2418 to controllably bend distal end 2418 (e.g., as shown by dashed line depiction 2419 of the distal end of flexible steerable body 2402). In embodiments where instrument system 2400 is actuated by a remotely operated assembly (such as remotely operated assembly 2302), housing 2404 can include a drive input that is detachably coupled to and receives power from an electrically driven element of the remotely operated assembly. In embodiments where instrument system 2400 is fully or partially manually operated, housing 2404 can include gripping features, manual actuators, or other components for manually controlling the movement of instrument system 2400. The instrument system 2400 can be steerable, or alternatively, the system can be non-steerable and have no integrated mechanism for operator-controlled instrument bending. Also or alternatively, one or more lumens are defined in the wall of the flexible steerable body 2402 through which the medical device can be deployed and used at the target surgical site.
[0172] In various embodiments, the medical device system 2400 can include a flexible device suitable for navigation operated by the navigation system 2432 and for treating tissue in any of a variety of anatomical systems via natural or surgically created connecting passages, including the colon, intestines, kidneys, brain, heart, circulatory system, pulmonary system, stomach, other gastrointestinal tracts, and the like.
[0173] exist Fig.24A In the embodiment of the present invention, the instrument system 2400 is remotely operated within the manipulator system 2300 operated by the navigation system 2432, which can provide an interface through the display system 2410. In alternative embodiments, the remote operation component 2302 can be replaced by direct operator controls. In the direct operation alternative, various handles and operator interfaces for handheld operation of the instrument can be included.
[0174] like Fig. 24B, medical devices (such as medical device 2426) for procedures such as surgery, biopsy, ablation, illumination, irrigation, or suction can be deployed through one or more channels of the flexible steerable body 2402 and used at a target location within the anatomical structure. The medical device 2426 can also be used with an image capture device (e.g., an endoscope) within the flexible steerable body 2402. Alternatively, the medical device 2426 itself can be an image capture device. The medical device 2426 can be advanced from the opening of the channel 2421 to perform the procedure, and then retracted into the channel 2421 when the procedure is completed. In some embodiments, optionally, the medical device 2426 can be removed from the proximal end 2417 of the flexible steerable body 2402, or removed from another optional instrument port (not shown) along the flexible steerable body.
[0175] Other configurations of teleoperated manipulator systems are also contemplated, such as systems configured for multi-port or single-port procedures. Surgical systems such as the da Vinci or surgical systems, all of which are commercialized by Intuitive Surgical of Sunnyvale, California.
[0176] Fig.25 An example embodiment of a manipulator system 2500 that can be used as part of the manipulator system 2300 is shown. The manipulator system 2500 includes a base 2520, a main column 2540, and a main boom 2560 connected to the main column 2540. The manipulator system 2500 also includes a plurality of manipulator arms 2510, 2511, 2512, 2513, each of which is connected to the main boom 2560. The manipulator arms 2510, 2511, 2512, and 2513 can be used as the manipulator assembly 2302. Each of the manipulator arms 2510, 2511, 2512, 2513 includes an instrument mounting portion to which an instrument 2530 can be mounted, which is shown attached to the manipulator arm 2510. Although the manipulator system 2500 depicts four manipulator arms, various embodiments can include more or fewer manipulator arms.
[0177] According to one embodiment, the instrument mounting portion may include a drive assembly 2523 and a cannula mount 2524, with a transmission mechanism 2534 of the instrument 2530 connected to the drive assembly 2523. The cannula mount 2524 is configured to hold a cannula 2536, through which the shaft 2532 of the instrument 2530 can extend to the surgical site during a surgical procedure. The drive assembly 2523 contains various drive and other mechanisms that are controlled to respond to input commands at the operator input system 2306 and transmit force to the transmission mechanism 2534 to actuate the instrument 2530. Although Fig.25 The embodiment shows the instrument 2530 attached only to the manipulator arm 2510 for ease of viewing, but the instrument may be attached to any and each of the manipulator arms 2510 , 2511 , 2512 , 2513 .
[0178] Reference now Fig.26 , shows a portion of an embodiment of a manipulator arm 2640 of a manipulator system with two surgical instruments 2600, 2610 in an installed position. For simplicity, Fig.26 The schematic diagram of only shows two surgical instruments, but as is familiar to those skilled in the art, more than two surgical instruments can be mounted at the mounting location of the manipulator system. Each surgical instrument 2600, 2610 includes a shaft 2620, 2630 having a movable end effector or endoscope, camera or other sensing device at the distal end, and may or may not include a wrist mechanism (not shown) for controlling the movement of the distal end.
[0179] exist Fig.26 In the embodiment of the present invention, the distal end portions of surgical instruments 2600, 2610 are received through a single port structure 2680 to be introduced into the patient's body. As shown, the port structure includes a cannula and an instrument entry guide inserted into the cannula. Individual instruments are inserted into the entry guide to reach the surgical site.
[0180] The transmission mechanisms 2685, 2690 are disposed at the proximal end of each shaft 2620, 2630 and are connected to the drive assembly 2720, 2730 via sterile adapters 2700, 2710, which includes various internal mechanisms (not shown) that are controlled by a controller (e.g., on a control cart of the surgical system) to respond to input commands at the surgeon-side console of the surgical system, thereby transmitting force to the transmission mechanisms 2685, 2690 to actuate the surgical instruments 2600, 2610.
[0181] Manipulator and instrument systems 2300, 2400, and 2500 and instruments 2426, 2530, and 2600 are examples of delivery devices that can be used to deliver electrolytic electroporation as described herein. For example, instruments 2426, 2530, and 2600 can include electrode end effectors as described herein (e.g., optionally with expandable members) to generate and deliver electrolytic electroporation to target tissue. The manipulator systems described herein are not limited to Fig.23 , Figure 24A-24B , Fig.25 and Fig.26 Various other teleoperated, computer-assisted manipulator configurations may be used with the embodiments described herein. The diameter or diameters of the instrument shaft and end effector are typically selected based on the size of the cannula to be used with the instrument and depending on the surgical procedure being performed.
[0182] The disclosed catheter and system can be used in a variety of different tissue locations. Rapid Tissue Regeneration Known tissue locations may be good choices for electrolytic electroporation tissue regeneration. For example, the catheter and system can be used in the small intestine, kidney, heart and other types of tissue.
[0183] Example
[0184] The small intestine was chosen as a model to demonstrate the ability of electrolytic electroporation to precisely ablate a controlled volume, thus ensuring that electrolytic electroporation ablation does not impair tissue regeneration processes.
[0185] Figure 5A 50 is a schematic diagram of an anatomical structure arranged according to examples described herein. The anatomical structure includes a liver 502, a stomach 504, a pancreas 506, and a duodenum 508. An example of a delivery system described herein can deliver an electric field, and thus electroporation and electrolysis, to the duodenum 508.
[0186] Figure 5B is a schematic diagram of anatomical structures arranged according to examples described herein. Figure 5B is a more detailed view of the anatomical features of the duodenum 508 .
[0187] These examples are provided to show examples of parameters of electroporation combined with electrolysis that allow for tissue regeneration and to demonstrate that electroporation and electrolysis can be precisely delivered.
[0188] Minimally invasive regenerative surgery using electrolytic electroporation was performed in the duodenal and jejunal mucosa as an example of controlled electrolytic electroporation for an ablation mode that favors regeneration of ablated tissue.
[0189] The purpose of these examples was to verify that electrolytic electroporation can precisely ablate a desired volume of tissue and to verify that electrolytic electroporation ablation is used in a manner that does not impede the ability of tissue in the ablated volume to regenerate. To explore these aspects of electrolytic electroporation ablation, porcine duodenal mucosa was used as an experimental model. Duodenal mucosa typically has the ability to regenerate from injury within three to seven days.
[0190] These examples include several parts. A mathematical model of the electric field around the electrodes is developed. The model is used to calculate the voltage on the electrodes in one of the electrolytic electroporation catheters or systems that generates a reversible electroporation electric field in the duodenal mucosa. As described above, and as Figure 1 As shown, the catheter or system is connected to a power source that can generate a precise voltage and deliver a predetermined charge through the electrodes.
[0191] A series of acute studies were conducted to evaluate the ability of the electrolytic electroporation technique to ablate only to a penetration depth into the deep mucosa without causing coagulative necrosis within underlying muscle layers (e.g., those containing visceral muscle cells) and to investigate the effects of various treatment parameters on the extent of ablation within a mathematically calculated range. A subsequent study was conducted in which the electrolytic electroporation parameters for mucosal ablation determined in the previous section were used. The effects of this treatment were followed up histologically up to eight days after the electrolytic electroporation treatment to verify that the tissue ablated with electrolytic electroporation had the ability to regenerate. These examples used discharges across a 1500 ohm resistor in series with the tissue resistance between the electrode pair in a voltage range of 100 V to 1000 V and a capacitance between 50 μF and 3500 μF.
[0192] Mathematical Model I
[0193] A mathematical model was developed to evaluate Figure 2A and Figure 2B The electric field around the expandable member 220 of the illustrated embodiment. This mathematical model can be used to determine the electric fields used in other examples of electrolysis and electroporation applications described herein. Figure 6 The tissue 10 of the small intestine is shown with the expandable member 220 of the catheter 200 disposed within the lumen 12 of the small intestinal tissue 10. The expandable member 220 and the electrodes 230 disposed on the outer surface 226 of the expandable member 220 are pressed against the mucosa 14 along the axis of the duodenum. The illustrated embodiment utilizes 16 electrodes that are equally spaced around the outer surface 226 of the expandable member 220. However, as described above, the number of electrodes may range from 2 to 30 electrodes, or some other number of electrodes may be used. Figure 6Also shown are the various tissue layers of the small intestine 10. The tissue layers 10 of the small intestine include the mucosa 14, the submucosa 16, the inner circular muscle layer 18, the outer longitudinal muscle layer 20, and the serosal surface 22. The interface 15 between the mucosa and the submucosa 16 is about 0.85 mm from the outer surface 226 of the expandable member 220 (e.g., the depth of the mucosa layer is 0.85 mm). The reference numerals for these tissue features are shown throughout. Figure 8 -Retained in Figure 20.
[0194] The electric field generated by the electrode 230 can be determined by solving Maxwell's equations on a two-dimensional cross-sectional finite element model of the expandable member 220, the plurality of electrodes 230, and the surrounding tissue 10 of the small intestine. The model simulates the electric field around the cross section in the expandable member 220 in a plane perpendicular to the duodenal axis of the small intestine 10. COMSOL Multiphysics (version 5.5) was used for the analysis. Fig.28A The electric field equation is expressed in , where E is for free space and the space charge density is ρ, where ∈0 is the absolute dielectric constant. The electric field is given by Fig.28B The relationship expressed by the equation is related to the potential field V. The electric displacement field D is defined as Fig.28C where P is the polarization vector field. Based on the above definition, the equation (also called Gauss's law) is Fig.28D shown.
[0195] Example 1 - Mathematical Model
[0196] This analysis simulates an experiment in which the expandable member 220 is expanded to a diameter of 30 mm. In the direction away from the catheter, the electric field decreases outward from the electrode surface. For safety reasons, and in order not to affect the muscular layer outside the submucosa, the electric field is set to a level that produces reversible electroporation at a distance of about 0.85 mm from the outer surface 226 of the balloon (e.g., at the outer edge of the mucosa). Because the electric field decreases outward from the catheter, the electric field strength beyond the mucosa into the submucosa and muscular layer is below the level required for cell membrane permeability. Therefore, the examples described herein (e.g., Figure 1 A system) can generate an electric field at a location in the tissue where the electric field will permeabilize the cells desired for ablation, but may not affect other cells that do not require ablation. For example, a permeabilizing electric field can be provided at a certain depth to affect (e.g., permeabilize) the mucosa and / or submucosa, but not the underlying muscle layer. Note that as described herein, some permeabilization and / or ablation of the submucosa may be acceptable using reversible electroporation and electrolysis, in part because the submucosa can regenerate and heal damage that may be caused when the mucosal layer is ablated. In this model, the thickness of the mucosa 14 is 0.85 mm, and the thickness of the muscle layers 18, 20 is 2.15 mm. In the calculation of the electric field, the relative dielectric constant of the muscles 18, 20 is taken as 66, and the relative dielectric constant of the mucosa is taken as 44.79.
[0197] The mathematical model is used to determine the electric field at the interface 15 between the mucosa 14 and the submucosal layer 16. Specifically, the mathematical model is applied to (a) 0.5 mm electrodes symmetrically arranged around the balloon and (b) flat electrodes attached to the balloon such that the surface of the electrode 230 and the outer surface 226 of the expandable member 220 adjacent to the electrode 230 are equal and the electrode 230 is also symmetrically arranged around the outer surface 226 of the expandable member 220.
[0198] The calculations were performed with a voltage of 500V between adjacent electrodes 230. However, the electric field scales linearly based on the applied voltage. For example, applying a voltage of 1000V will produce an electric field that is twice as large as the electric field produced by applying a voltage of 500V, and applying a voltage of 250V will produce an electric field that is half the electric field produced by applying a voltage of 500V. 12, 14, and 16 electrodes were analyzed. For different numbers of electrodes, Fig.29 The table in summarizes the electric field range for both the circular electrode and the surface electrode at 0.85 mm from the outer surface 226 of the expandable member 220. The flat electrode produces a slightly higher electric field with a narrower range.
[0199] It is obvious that the greater the number of electrodes 230, the higher the electric field. In addition, the maximum electric field at 0.85 mm is much lower than the electric field used in irreversible electroporation. Since the electric field decays with distance from the electrode and catheter surface, these electric fields cannot produce irreversible electroporation, and any cells within this range are only affected by the ablation mechanism of combined reversible electroporation and electrolysis.
[0200] Example 2 - Mathematical Model
[0201] Example 2 for Figure 3 The catheter 300 is shown. As described above, the catheter 300 includes two axial electrodes 332, 334, wherein the space between the catheter and the intestine is filled with a conductive gel 318. The electric field generated by electrodes of different sizes and the space between the electrodes can be simulated to confirm the electrode size, spacing, and voltage application to generate a field strength sufficient to cause reversible electroporation in the mucosal layer.
[0202] Example 3 - Mathematical Model
[0203] Example 3 for Figure 4 System 400 is shown. In mathematical analysis, system 400 is modeled as a monopolar cylindrical electrode 430 in the intestine 10 and a ground pad on the external surface of the body. Fig. 30A The equation represents the relationship between the potential V around the cylindrical conduit 410 with radius r1 and the potential V0 around the ground pad 440 on the outer surface r2. The field is calculated as Fig. 30BTherefore, the potential V0 can be calculated as Fig. 30C The equation of .
[0204] Assuming r1 = 1.75 cm and r2 = 30 cm, for r = 2 cm and an electric field of 300 V / cm at 2 cm, we obtain: V0 = 1704 V, and the electric field on the electrode at r1 is 341 V / cm.
[0205] Assuming r1 = 1.75 cm and r2 = 10 cm, for r = 2 cm and an electric field of 300 V / cm, we obtain: V0 = 1045 V, and the electric field at the electrode at r1 is 342 V / cm.
[0206] Example 1 - Animal Model
[0207] In the animal model, a 67.3 kg female Yorkshire pig was used. A 24-hour study was used to fully evaluate the ablation site and effect at the cellular level within the intestinal wall layer. In addition to confirming the parameters that can achieve deep mucosal ablation, the animal study also confirmed that electrolytic electroporation can achieve precise ablation depth without the need for mucosal layer isolation. Figure 6 is a schematic diagram of the small intestine and mucosa 14 showing targeted ablation.
[0208] Animals were fasted for 24 hours prior to the procedure (n=2; 60-65 kg). TM Alcohol-based CHG (BD, Vernon Hills, IL) was used as a preoperative skin preparation on the abdomen. Animals were prepped and draped in the usual sterile manner. Preoperative antibiotics (broad-based cephalosporin) were given before incision.
[0209] Fig. 7A and Figure 7B A schematic diagram showing a medical procedure for inserting an electrolysis electroporation catheter or system.
[0210] Fig. 7A A delivery system (a catheter in the example shown) is shown being delivered to the duodenum to ablate the mucosal lining according to examples described herein. Fig. 7A The duodenum 714 is shown in its anatomical context. Fig. 7AAlso shown in the figure are stomach 702, pylorus 704, bile duct 706, bile duct 708, plexus 710, pancreas 712, superior mesenteric vessels 720, mucosal lining 722, and ligament of Treitz 724. Endoscope 726 can be delivered to duodenum 714 in an oral manner. Thus, endoscope 726 can be delivered to duodenum 714 through esophagus and / or stomach. The catheter can be delivered by endoscope 726, such as by delivering in the working channel of endoscope 726. Endoscope 726 can include other components, including but not limited to one or more cameras, (one or more) light sources, and / or (one or more) other sensors. The shaft 716 of the catheter can be positioned in the duodenum 714. Expandable member 718 can be coupled to shaft 716 and can be expanded in the treatment area. Expandable member 718 can include electrodes for applying the electric field described herein, such as a linear electrode array. In this way, the catheter can be used to treat mucosal lining 722. In some examples, the area to be ablated can surround the expandable member 718, and ablation of the mucosal lining 722 can be targeted without affecting adjacent tissue.
[0211] Although Fig. 7A The examples of show the use of a delivery system including an endoscope that can be used to deliver a catheter to a treatment area, but other delivery systems can also be used in addition or instead. For example, the delivery system can be implemented using a computer-assisted teleoperated manipulator system, which is sometimes also referred to as a robotic-assisted system or a robotic system. For example, reference Figure 23-Figure 26 The robotic system shown and described may be used to control and / or deliver a catheter through an endoscope described with reference to the robotic system. In some examples, one or more electrodes may be provided as a reference Figure 23-Figure 26 One of the instruments described in the robot control system.
[0212] Figure 7B The catheter 200 is shown inserted into the small intestine 10 using a surgical hole created for experimental access; however, the present disclosure is not limited thereto or to other methods used therewith, and any of the catheters or systems described above may be used. The catheter 200 is inserted into the gastrostomy 32. A purse-string suture 34 is placed around the gastrostomy 32 to help secure the catheter 200. The catheter 200 is secured with an envirocide TM (Metrex Research, Orange, CA) to decontaminate catheter 200.
[0213] The catheter 200 was then manually advanced into the mid-jejunum. Although the safety study was primarily targeted at the duodenum, the jejunum was also used in the study in order to maximize the number of ablation sites per animal, as the duodenum is approximately 8 to 10 cm in length, allowing only three separate non-overlapping ablation sites. Electrolytic electroporation duodenal mucosal regeneration (DMRe) was then performed from the mid-jejunum back toward the proximal duodenum, working from distal to proximal. Once in position, the expandable member 220 of the catheter 200 was insufflated under direct visualization to ensure circumferential tissue adherence. Electrolytic electroporation pulses were then delivered to the tissue (range: 100V to 1000V, 1 to 10 pulses). Fifteen lesions were created in each animal, for a total of 30 electrolytic electroporation ablation sites. Very mild muscle tremors were observed with pulsed ablation; however, no severe muscle contractions or plasma arcing were observed with the delivery of the electrolytic electroporation range to achieve DMRe. After each electrolytic electroporation ablation, the lesion was marked directly in the middle of each ablation zone for easy access with a large metal vascular clip (Weck, Teleflex, Morrisville, NC) on the mesenteric surface. TM Horizon Clips TM ) for identification. Be careful not to ligate any mesenteric artery supply branches that may affect intestinal blood flow. The catheter 200 is compressed (e.g., shrunk) and then manually retracted using touch to space out the electrolytic electroporation ablation lesion throughout the small intestine 10. Active electrolysis can be roughly seen on the serosal surface 22 of the intestinal wall, and the tissue temporarily becomes gray and discolored. A total of 15 ablations were performed. After 15 electrolytic electroporation ablations were completed in each animal, the catheter 200 was removed and the gastrostomy 32 was repaired. The tissue 10 of the small intestine was visually inspected, and no damaged tissue at risk of necrosis was observed on the serosal surface 22 of the proximal small intestine of any animal. The midline laparotomy 30 was then closed. Each animal was then observed for 24 hours and tolerated a clear diet. No adverse events were observed.
[0214] Each animal was then euthanized 24 hours later. The proximal intestine was dissected with the pancreas and mesenteric segments attached. Each ablation site was then removed and fixed in formalin. Histological analysis (whole volume analysis, H&E) was then performed to assess tissue viability and electrolytic electroporation ablation depth in order to confirm the parameters to achieve transmucosal ablation without causing full-thickness damage to the intestine.
[0215] Figure 8-Figure 11 is a micrograph of a small intestine section ablated using the electrolytic electroporation power supply and catheter 200 and the exponential decay wave generator power supply 102. Figure 8-Figure 11is an image showing staining with H&E. Lesion boundaries, i.e., width and depth of treatment penetration, are enclosed within black circles or squares where applicable. The ablation effect is variable, with lesions being punctate, multifocal, and / or locally extensive, involving the mucosa and submucosa, and / or extending through the entire thickness of the bowel wall. Multifocal lesions are often interrupted by circumferential wedges of normal mucosa. In cases with less tissue-affected tissue, the damage is confined to the mucosa, with necrosis and sloughing of the upper half of the villi (resembling an ulcer), while the lower half of the villi have intimal epithelial cells that appear somewhat like "ghost cells" that preserve the architectural contours. These ghost cells are considered to be essentially inactive. Necrosis is accompanied by congestion and / or hemorrhage and infiltration of polymorphonuclear leukocytes, primarily neutrophils. In more severely affected cases, the ablation effect is relatively more pronounced, with complete destruction of the mucosa and submucosa, with or without involvement of the outer muscle layer of the serosa. No bowel wall perforation was noted at any particular site.
[0216] Figure 8 A cross section perpendicular to the axis of the intestinal tissue 10 and a high magnification of a specific ablation site are shown (circles). Electrolytic electroporation was applied with a voltage of 500V, a capacitance of 100μF, a resistance of 15-20 ohms, a pulse, and a time constant of 1.8ms. The results of electrolytic electroporation were mucosal ablation and superficial and deep mucosal ablation, the submucosal layer and muscle remained intact, the villus tips were ablated, submucosal edema was minimal, and the ablation was controlled within the mucosa. There was 90% mucosal ablation.
[0217] Fig. 9 A cross section perpendicular to the axis of the intestinal tissue 10 and a high magnification of a specific ablation site are shown (circles). Electrolytic electroporation was applied with a voltage of 500V, a capacitance of 100μF, a resistance of 15-20 ohms, 2 pulses, and a time constant of 1.7ms. The time interval between pulse delivery was approximately one minute. The result of electrolytic electroporation was 75% mucosal ablation, with the submucosal layer and muscle remaining intact. The scaffold of intestinal tissue 10 was well preserved.
[0218] Fig.10 A cross section perpendicular to the axis of the intestinal tissue 10 and a high magnification of a specific ablation site are shown (circles). Electrolytic electroporation was applied with a voltage of 500V, a capacitance of 100μF, a resistance of 15-20 ohms, 5 pulses, and a time constant of 1.7ms. The time interval between pulse delivery was about one minute or less. The result of electrolytic electroporation was 100% ablation of the entire mucosa and submucosa, with the muscularis remaining intact.
[0219] Fig.11A cross section perpendicular to the axis of the intestinal tissue 10 and a high magnification of a specific ablation site are shown (circles). Electrolytic electroporation was applied with a voltage of 500V, a capacitance of 100μF, a resistance of 15-20 ohms, 10 pulses, and a time constant of 1.7ms. The time interval between pulse delivery was about one minute or less. The result of electrolytic electroporation was that the muscularis remained intact, the mucosa and deep intramucosal ablation, some submucosal ablation, and 90% overall mucosal ablation.
[0220] Figure 8-Figure 11 Electrolytic electroporation was generated using 16 circular electrodes 230 with a diameter of 0.88 mm. The electric field at the interface 15 between the submucosal layer 16 and the mucosa 14 was calculated to be between 850 V / cm and 450 V / cm, which is within the range of reversible electroporation. Between the outer surface of the catheter and the interface 15, the electric field did not exceed the reversible electroporation electric field range of about 1000 V / cm to 1200 V / cm. In some electrode configurations with sharp edges, there may be some local singular points in the irreversible electroporation electric field. The maximum temperature was modeled as 45.88°C at the electrode surface at 0.5ms of the applied energy. The ambient temperature was below 40°C. Figure 5- Figure 8 showed that the range of ablation was limited by the range of the electric field inducing electroporation and did not exceed this range regardless of the number of pulses.
[0221] Fig.12 A catheter 200 is shown for producing Figure 8-Figure 11 The results of the experiments performed with the power supply show the effect. However, when the voltage was increased to 750V and the capacitance was increased to 50μF, for example, the amount of electrolytic products was halved. The electric field at the interface 15 between the mucosa 14 and the submucosal layer 16 was between 1125V / cm and 675V / cm. The overall parameters were a voltage of 750V, a capacitance of 50μF, a resistance of 15-20 ohms, 1 pulse and a time constant of 0.529 seconds. Histology showed the presence of superficial ablation of the mucosa 14. In total, 25% to 30% of the mucosa was ablated. The results of electrolytic electroporation show that despite the increase in the electric field, the reduction in electrolytic products reduces the extent of ablation.
[0222] Fig.13 A catheter 200 is shown for producing Figure 8-Figure 11The results of the experiment were performed with power supply 102. However, the voltage was raised to 1000V and the capacitance was raised to 50μF, for example, and the amount of electrolysis products was halved. The electric field at the interface 15 between the mucosa 14 and the submucosal layer 16 was between 1700V / cm and 900V / cm. The overall parameters were a voltage of 100V, a capacitance of 50μF, a resistance of 15-20 ohms, 1 pulse, and a time constant of 0.532 seconds. This treatment was associated with an arc, which is a typical feature of irreversible electroporation parameters. In fact, 1700V / cm is within the range of irreversible electroporation parameters. This indicates that the entire mucosa 14 from the electrode to the submucosal layer 16 was exposed to irreversible electroporation parameters. (It should be noted that when delivering reversible electroporation, it is expected that some irreversible electroporation may occur near the electrode.) The result of the electrolytic electroporation was 25% transmural ablation. This experiment illustrates the possible problems of irreversible electroporation ablation in the intestine 10. For example, irreversible electroporation may damage cells, resulting in scar tissue or other obstacles to tissue regeneration.
[0223] Fig.14A and Fig. 14B A catheter 200 is shown for producing Figure 8-Figure 11 The results are of the effect of the power supply on the experiments conducted. Fig. 14B yes Fig.14A However, the voltage is kept at 500 V, and the capacitance is increased to 250 μF, for example, the amount of electrolysis products is Figure 8-Figure 11 2.5 times the value used in the experiment. The electric field at the edge of the mucosa is Figure 8-Figure 11 The same range was between 450 V / cm and 850 V / cm. The overall parameters were a voltage of 500 V, a capacitance of 250 μF, a resistance of 15-20 ohms, 1 pulse, and a time constant of 3.6 ms. Histology showed transmural ablation, ulceration, and coagulation of submucosal and muscle areas. In general, there was 20% ablation and 10% transmural ablation. This experiment demonstrates the potential impact of transient delivery of large amounts of electrolytic products.
[0224] Figure 8-Figure 1 The set of experiments shown in 4 demonstrates that (1) it is possible to design an electrolytic electroporation treatment protocol that precisely ablates targeted tissue, (2) increasing the electric field to the irreversible electroporation range may cause undesirable damage, and (3) increasing the amount of electrolysis products may also cause undesirable damage. The conclusion is that electrolytic electroporation can produce the desired ablation pattern; however, it must be precisely designed and delivered for the intended application. This suggests that precise ablation and subsequent regeneration using electrolytic electroporation is a surprising and unexpected result of the combination of electrolysis and electroporation. For example, parameters can be used so that the extracellular matrix of the ablated tissue remains intact, which is conducive to tissue regeneration.
[0225] 24-hour, 3-day, and 8-day tissue regeneration studies
[0226] The porcine model was chosen due to its structural similarity to humans in terms of diameter and intestinal wall thickness.
[0227] A previous 24-hour porcine study confirmed electrolytic electroporation parameters that achieved transmucosal ablation to the level of the submucosal layer without disrupting or causing necrosis of the muscularis. This confirms proof of concept that judicious delivery of electrolytic electroporation can achieve precise mucosal depth ablation. This demonstrates duodenal mucosal regeneration after treatment with electrolytic electroporation parameters confirmed in a previous series of experiments. In a series of three pigs, the use of Fig.29 The parameters listed in the table were used for the regeneration process in the animals treated. The catheter 200 and power supply were the same as in the previous experiments.
[0228] Animals were fasted for 24 hours prior to the procedure (n=3; 60-65 kg). TM Alcohol-based CHG (BD, Vernon Hills, IL) was used as a preoperative skin preparation on the abdomen. Animals were prepped and draped in the usual sterile manner. Preoperative antibiotics (broad-based cephalosporin) were given before incision.
[0229] As mentioned above, Fig. 7A and Figure 7B A schematic diagram illustrating a medical procedure for inserting an electrolysis-electroporation electrode catheter or system. Fig. 7A A midline laparotomy and exteriorization of the small intestine 10 are shown. In some embodiments, the stomach 2 may also be exteriorized. In order to manually advance an electrolysis electroporation catheter or system into the proximal small intestine 10, a gastrostomy 32 is created for surgical access.
[0230] Figure 7B The catheter 200 is shown inserted into the small intestinal tissue 10 through the gastrostomy 32. A purse string suture 34 is placed around the gastrostomy to help secure the catheter 200. The catheter 200 is envirocide TM (Metrex Research, Orange, CA) to purify the equipment.
[0231] The catheter 200 was then manually advanced into the mid-jejunum for each animal. Although the safety study was primarily targeted at the duodenum, the jejunum was also used in the study to maximize the number of ablation sites per animal, as the duodenum is approximately 8 to 10 cm long, allowing only three separate non-overlapping ablation sites. Electrolytic electroporation DMRe was then performed from the mid-jejunum back toward the proximal duodenum, working from the distal to the proximal side. Once in position, the expandable member 220 of the catheter 200 was then insufflated under direct visualization to ensure circumferential tissue adhesion. Electrolytic electroporation pulses were then delivered to the tissue (range: 500V, 1, 2, and 5 pulses). Twelve ablations were performed on each animal, for a total of 36 ablations. Three single-pulse lesions, three double-pulse lesions, and five five-pulse lesions were observed in each animal. Fig.29 The table in is a list of the experiments conducted in this study.
[0232] Very mild muscle tremors were observed with pulsed ablation; however, no severe muscle contractions or plasma arcing were observed with the delivery of electrolytic electroporation zones to achieve DMRe. After each electrolytic electroporation ablation, the lesion was marked directly in the middle of each ablation zone for easy access with a large metal vascular clip (Weck, Teleflex, Morrisville, NC) on the mesenteric surface. TM Horizon Clips TM ) for identification. Care was taken not to ligate any mesenteric artery supplying branches that could affect intestinal blood flow. The catheter 200 was deflated (e.g., narrowed) and then manually retracted using tactile sensation to compartmentalize an electrolytic electroporation ablation lesion throughout the small intestine 10. Active electrolysis was generally visible on the serosal surface 22 of the intestinal wall, with a temporary gray discoloration of the tissue. A total of 15 ablations were performed. After completion of the electrolytic electroporation ablation, the catheter 200 was removed and the gastrostomy 32 was repaired. The tissue 10 of the small intestine was visually inspected, and no damaged tissue at risk for necrosis was observed on the serosal surface 22 of the proximal intestine 10. The midline laparotomy 30 was then closed. Each animal was then returned to the monitoring area and tolerated a clear diet. No adverse events were observed in any animal during the postoperative period.
[0233] Euthanasia was then performed at 24 hours, 3 days, and 8 days. The proximal intestine was dissected with the pancreas and mesenteric segments attached. Each ablation site was then removed and fixed in formalin. Histological analysis (whole volume analysis, H&E) was then performed to assess tissue viability and electroporation ablation depth in order to confirm the parameters for achieving transmucosal ablation without causing full-thickness injury to the intestine. On gross visualization and inspection at the time of transplantation, no intestinal necrosis, ulceration, stricture, or perforation was observed in any of the electroporation ablation areas.
[0234] While tissue regeneration is shown over 8 days in these examples, in some examples, tissue regeneration may occur over longer periods of time, including 10, 20, or 30 days, without scarring or fibrosis (eg, without collagen bands).
[0235] Fig.15A The mucosa of the control sample is shown. Fig. 15B Shown is the appearance of the mucosa 24 hours after treatment of the mucosa with a single electrolytic electroporation pulse of 500 V and 100 μF.
[0236] Fig.16A The mucosa of the control sample is shown. Fig. 16B Shown is the appearance of the mucosa 24 hours after treatment with two electrolytic electroporation pulses of 500 V and 100 μF. The two pulses appear to result in a more substantial mucosal ablation; however, the muscularis is intact.
[0237] Fig.17A and Fig. 17B Shown is the appearance of the mucosa 24 hours after treatment with five electrolytic electroporation pulses at 500 V and 100 μF. Fig.17A and Fig. 17B Different locations in the tissue are shown. Five pulses appear to result in more substantial mucosal ablation; however, the muscularis is intact and ablation is limited to the mucosa.
[0238] Figures 18A-18C The histology of tissue treated with five electrolytic electroporation pulses 24 hours after treatment is shown. The segments have areas of mucosal necrosis characterized by subacute damage to the mucosal epithelium with regeneration (already after 24 hours) as evidenced by the proliferation of basophilic immature crypt cells. There is persistent crypt expansion with or without necrotic debris. There is a slight to mild infiltration of mixed inflammatory cells (including macrophages, lymphocytes and a small number of neutrophils). Fig.18C The small circles show the cellular debris in the crypts. Fig.18C The small squares show the regenerating crypt epithelial cells. Fig.18C The large squares show a mixed inflammatory cell infiltrate consisting of macrophages (large cells with large nuclei); the small dark cells are lymphocytes, and the bright cytoplasmic cells with dumbbell-shaped nuclei are PMNs (polymorphonuclear leukocytes, neutrophils and / or eosinophils).
[0239] Fig.19A Shown is tissue ablated by electrolytic electroporation 72 hours (three days) after treatment with one pulse. Fig.19B Shown is electrolytic electroporation ablated tissue 72 hours (three days) after treatment with three pulses. Fig.19C Shown is electrolytic electroporation ablated tissue 72 hours (three days) after treatment with five pulses. Clearly, regardless of the number of pulses, the tissue is completely regenerated after three days. Fig.19D The mucosa of the control sample is shown, Fig.19E shows tissue treated with five electrolytic electroporation pulses 24 hours later, and Fig.19F Tissue treated with five electrolytic electroporation pulses after 72 hours is shown. The comparison shows that the five electrolytic electroporation pulses ablated the mucosa without affecting the muscularis, and that this ablation was evident after 24 hours. However, the tissue was completely regenerated 72 hours after treatment with five electrolytic electroporation pulses and 24 hours after ablation, as expected, without damage to the extracellular scaffold by ablation. This experiment shows that an electrolytic electroporation treatment protocol designed to ablate tissue allows it to regenerate.
[0240] Figure 20A-20C Shown is electrolytic electroporation ablated tissue eight days after electrolytic electroporation treatment. Fig. 20A The appearance after one pulse is shown. Fig. 20B The appearance after two pulses is shown. Fig. 20C The appearance after five pulses is shown. It is clear that regardless of the number of pulses, when the ablation did not damage the extracellular scaffold, the tissue was fully regenerated at eight days, as expected. In addition, the ablation depth can be controlled to achieve tissue regeneration within 30 days without scarring or fibrosis, loss of collagen bands, or ulceration. This experiment demonstrates the design of an electrolytic electroporation treatment protocol for ablation of tissue to make it regenerative, such as using electrolytic electroporation for tissue regeneration. Through this experiment, the process of electrolytic electroporation and the recovery of tissue can be confirmed.
[0241] Mathematical Model II
[0242] A mathematical model was developed to analyze the electric field distribution, dissipated heat energy, and temperature distribution. This mathematical model can be used to determine the electric fields used in the examples of electrolysis and electroporation applications described in this article. By solving Fig.31A The potential distribution associated with the electroporation pulse is determined by the Laplace equation of is the electric potential, and σ is the conductivity. The electrical boundary condition of the tissue in contact with the leftmost electrode(s) is expressed as Fig.31B The electroporation voltage on the leftmost electrode (one or more) is V0. The electrical boundary condition at the interface of the second electrode (one or more) is expressed as Fig.31C The boundaries of the analyzed domain that are not in contact with the electrodes are considered to be electrically insulating. The solution to these equations, along with the associated geometry and boundary conditions, gives the electric field distribution in the tissue. By solving for the electric field, the solution to the associated Joule heat (p), the rate of heat generation per unit volume due to the dissipation of the electric field, can be calculated, as Fig.31D This term is added to the original Pennes equation to represent the heat generated by the electroporation procedure, as Fig.31EAs shown, where k is the thermal conductivity of the tissue, T is the temperature, and w b is blood perfusion, c b is the heat capacity of blood, T a is the arterial temperature, q'' is the metabolic heat production, ρ is the tissue density, c p is the heat capacity of the tissue. The purpose of this part of the analysis is to determine the temperature distribution in the tissue. Thermal damage is a temperature and time dependent process where thermal damage is caused by Fig.31F In some examples, thermal damage may begin at temperatures above 42°C. However, in the temperature range of 50°C to 60°C, damage may be relatively low and occur within minutes to hours of exposure.
[0243] Example 2 - Animal Model
[0244] In this animal model, a 100 kg female Yorkshire pig was used. Animal studies have established a qualitative correlation between the number of pulses and the depth of ablation. A medical procedure similar to that shown in Example 1 - Animal Model was used, so for the sake of brevity, a detailed description of the medical procedure that has been previously described (such as in reference 1) will not be repeated herein. Fig. 7A and Figure 7B ).
[0245] In this example, a catheter (e.g., catheter 200) is then used to deploy an electrolysis electroporation electrode array of 16 electrodes, including 8 cathodes and 8 anodes, to achieve adequate tissue adhesion. The geometry analyzed is as follows Fig.32 As shown. The width of each electrode is 0.89 mm and the gap between electrodes is 4.31 mm. The diameter of the balloon is 26.5 mm. The catheter is guided to be manually advanced to the mid-jejunum and then returned from the mid-jejunum toward the proximal duodenum for electrolysis electroporation DMRe, working from distal to proximal. A 500V exponentially decaying waveform can be applied to the tissue via the axial electrode array, which is modeled to achieve 1000 kV / cm 2 Electrolytic electroporation ablation fields were created. Four treatment sites were performed in the duodenum and four in the jejunum, each measuring approximately 3 cm in length. A total of eight ablations were performed: two with one pulse, four with five pulses, and two with 10 pulses. The ablation sites were marked on the mesenteric surface of the small intestine at the midpoint of each ablation zone with an intravascular clip for site identification. Overlapping areas of ablation were simulated to understand potential safety issues and treatment effects of applying 10 pulses.
[0246] Each animal was then euthanized 5 to 6 hours after electrolytic electroporation ablation, and the proximal small intestine was resected and transplanted. The treatment area was then confirmed, and the tissue was processed by obtaining axial and longitudinal segments, which were then fixed in formalin for 24 hours, processed and fixed in paraffin blocks. The tissue samples were then stained with hematoxylin and eosin and Masson's trichrome staining. The segments were then evaluated to determine the depth and extent of the ablation. In addition, expert gastrointestinal pathologists provided annotations to determine the overall circumferential integrity of the ablation, which was correlated with the array to obtain the ratio of circumferential ablation (e.g., the amount of circumference of tissue in the affected target area). During the ablation, there were no changes in the hemodynamics of the animals. Mild muscle contractions were observed, and intraoperative muscle paralysis was not required.
[0247] Fig.33 is a table presenting the experimental results. The voltage was kept at 500V. The capacitance at sites 1A and 1B varied between 100μF and 1μF. For other sites, the capacitance was kept at 100μF. A voltage of 500V (peak) was used. The number of pulses varied from 1 to 5 to 10. When the capacitance was 1μF, there was no ablation. Therefore, the capacitance difference affects whether ablation may be caused. When the capacitance is constant at 100μF, the number of pulses may affect the ablation depth. For example, in this example, when the number of pulses was 1, the ablation depth of many sites was limited to the superficial mucosa. On the other hand, in this example, when the number of pulses was 5 or 10, the ablation depth reached deep mucosal ablation. In addition, in this example, when the number of pulses was 5, 50% of circumferential intracavitary ablation was achieved, while when the number of pulses was 10 in this example, 75% of circumferential intracavitary ablation was achieved. The results of electrolytic electroporation show that as the number of pulses applied to the target tissue increases, the ablation depth and the amount of ablation within a specific circumference also increase. Furthermore, the perimeter of tissue affected by ablation increases with increasing dosimetry (eg, number of pulses).
[0248] Example 3 - Animal Model
[0249] In this animal model, female Yorkshire pigs weighing approximately 60 kg were used. Animal studies further established a quantitative correlation between the number of pulses and the depth of ablation. A medical procedure similar to that shown in Examples 1 and 2 - Animal Model was used, and therefore, for the sake of brevity, a detailed description of the medical procedure previously described (such as in reference 1 and 2) will not be repeated herein. Fig. 7A and Figure 7B ).
[0250] In this example, a catheter (e.g., catheter 200) is then used to deploy an electroporation electrode array, including 16 titanium electrodes attached to its outer surface, to achieve adequate tissue adhesion. The catheter is guided to be manually advanced to the middle of the jejunum, and then returned from the middle of the jejunum toward the proximal duodenum for electroporation DMRe, working from the distal to the proximal side. A total of six treatment sites were performed on each animal: two in the duodenum and four in the jejunum. At the midpoint of each treatment site, each treatment site was marked with an intravascular clamp on the mesenteric surface of the small intestine. The total length of each treatment site was measured to be approximately 3 cm. Each animal was then euthanized 24 hours, 3 days, 8 days, and 30 days after electroporation ablation, and the proximal small intestine was removed and transplanted. The treatment area was then confirmed, and the tissue was processed by obtaining axial and longitudinal sections, which were then fixed in formalin overnight, processed, and fixed in paraffin blocks. The tissue samples were then stained with hematoxylin and eosin and Masson's trichrome staining. The segments were then evaluated to confirm the depth and extent of ablation. In addition, an expert gastrointestinal pathologist provided annotations to determine the overall circumferential completeness of the ablation, which was then correlated with the array to obtain a ratio of circumferential ablation.
[0251] Tissue regeneration studies at 24 hours, 3 days, 8 days and 30 days
[0252] Fig.34A and Fig.34B are schematic diagrams showing the relationship between the number of pulses and the average ablation depth of the jejunum and duodenum, respectively, in an example of the system described herein. Fig.35 is a diagram showing the relationship between the number of pulses and the percentage of circumferential ablation in an example of the system described herein. Samples collected 24 hours after surgery showed circumferential ablation of 19-40%, indicating that the mucosa was partially healed at this time. Similarly, the longitudinal percentage ablation along the length of the mucosa showed 13-34% ablation. Fig.34A , Fig.34B and Fig.35 As shown, there is an efficacy-dependent correlation between the number of pulses (i.e., dose intensity) and the percentage of circumferential ablation achieved. The ablation depth ranged from 0.4 mm to 0.6 mm, indicating limited depth to the submucosal layer. There was a positive correlation between the number of pulses and the depth. The maximum ablation depth ranged from 0.6 mm to 1.2 mm, reaching a peak of approximately 1.0 mm at 10 pulses. The results of electrolytic electroporation showed that as the number of pulses increased, the ablation depth and ablation rate also increased.
[0253] Samples collected on the third and eighth postoperative days showed no evidence of tissue damage and were histologically identical to control samples. Villi architecture appeared normal, and complete recovery of the mucosa was observed even at the highest pulse number. External mild serosal adhesions were visible in some samples, indicating physical manipulation of the intestine during the gastrotomy. No transmural damage was observed, nor was there any collagen deposition, which could be an early sign of fibrosis. Likewise, there was no evidence of epithelial damage, and complete healing was achieved after 30 days. Gross visualization of the treated site showed no signs of perforation or stenosis. Villi architecture appeared normal, and there was no inflammation at the treated site. Some samples showed extensive proliferation of microvessels adjacent to the mucosa at 30 days, indicating healthy regeneration of the duodenal mucosa. This was only observed at sites treated with 10 pulses. The results of electrolytic electroporation showed that as the number of pulses increased, the ablation depth and ablation rate also increased, resulting in healthy regeneration of the duodenal mucosa.
[0254] This capability can be extended to implanting and / or transplanting stem cells, molecules, genetic material, organoids, or other desired cells in electrolytically electroporated ablated tissues prior to and during ablation to regeneration.
[0255] The examples of design and clinical application of the delivery systems provided herein are not limited to the use of a combination of electroporation and electrolysis while retaining the extracellular matrix. There are many configurations of delivery systems, and applications that would benefit from the use of the techniques described herein.
[0256] It should be understood that according to the present systems, devices and methods, any one of the above-described embodiments or processes may be combined with one or more other embodiments and / or processes, or separated and / or performed between separate devices or device parts.
[0257] Finally, the above discussion is intended only to illustrate the present apparatus, devices, systems and methods and should not be interpreted as limiting the appended claims to any particular embodiment or group of embodiments. Therefore, although the present disclosure has been described in particular detail with reference to exemplary embodiments, it should also be understood that many modifications and alternative embodiments may be practiced without departing from the broader and intended spirit and scope of the present disclosure set forth in the appended claims. Therefore, the description and drawings should be regarded as illustrative and are not intended to limit the scope of the appended claims.
Claims
1. A method, include: positioning at least one electrode proximate to tissue of a patient; applying an electric field to at least a portion of the patient using the at least one electrode, the electric field configured to permeabilize cell membranes in a targeted tissue of the patient, thereby producing permeabilized cells, wherein the permeabilized cells are within an area targeted for ablation; and Electrolysis is performed to generate electrolytic products in the target tissue, thereby ablating the permeabilized cells while maintaining an intact extracellular matrix in the target tissue. 2 . The method of claim 1 , wherein the positioning comprises delivering a catheter to the patient, the catheter comprising the at least one electrode.
3. The method of claim 2, wherein said applying the electric field comprises applying a voltage between said at least one electrode and a return electrode positioned proximate to said patient.
4. The method of claim 2, wherein the catheter comprises a pair of electrodes, the pair of electrodes comprising the at least one electrode, and wherein applying the electric field comprises applying a voltage between the pair of electrodes.
5. The method of claim 1, wherein the extracellular matrix provides a scaffold for tissue regeneration.
6. The method of claim 1, wherein the electrolysis product does not form scar tissue, fibrotic tissue, coagulative necrosis, ulcers, or a combination thereof.
7. The method of claim 1, wherein applying the electric field comprises delivering pulses between 100 V and 1000 V with a capacitance between 50 μF and 100 μF. The method of claim 6 , wherein the number of pulses is between 1 and 10.
9. The method of claim 1, wherein the number of pulses is selected based on ablation depth.
10. The method of claim 1, wherein the generated electric field is between 450 V / cm and 850 V / cm.
11. The method of claim 1, wherein the target tissue is the mucosal layer of the small intestine.
12. The method of claim 11, wherein the field strength of the electric field at the interface between the mucosal layer and the submucosal layer is less than the field strength used for irreversible electroporation.
13. The method of claim 12, wherein the electric field at the interface between the mucosal layer and the submucosal layer is less than 850 V / cm.
14. The method of claim 11, wherein the electric field at the interface between the mucosal layer and the submucosal layer is between 450 V / cm and 850 V / cm.
15. The method of claim 1, further comprising introducing additional cells into the targeted tissue by transplantation, migration, or a combination thereof, wherein the additional cells facilitate regeneration.
16. A system for performing electrolytic electroporation regeneration, include: a delivery system having a plurality of electrodes configured to contact a tissue region targeted for ablation; a controller configured to control the charge applied to the electrodes, the controller being configured to: inducing a voltage to produce permeabilized cells in the tissue region targeted for ablation; as well as An electric current is induced to produce electrolytic products to cause ablation of the permeabilized cells while maintaining the extracellular matrix of at least some of the permeabilized cells intact to allow regeneration of the tissue including the permeabilized cells.
17. The system of claim 16, wherein the delivery system comprises a catheter, and wherein a distal portion of the catheter comprises an expandable member configured to contact the tissue region targeted for ablation, the expandable member comprising the plurality of electrodes.
18. The system of claim 17, wherein the plurality of electrodes extend from a proximal portion to a distal portion of the extendable member.
19. The system of claim 16, wherein the plurality of electrodes is between 12 electrodes and 16 electrodes.
20. The system of claim 16, wherein the plurality of electrodes are circular and generate an electric field between 350 V / cm and 900 V / cm.
21. The system of claim 16, wherein the electrode has a flat surface and generates an electric field between 580 V / cm and 930 V / cm.
22. The system of claim 16, further comprising a power supply that delivers pulses between 100V and 1000V with a capacitance between 50μF and 100μF.
23. The system of claim 16, wherein the controller is configured to select the number of pulses based on ablation depth.
24. A non-transitory computer-readable storage medium comprising instructions which, when executed by a controller, cause the controller to: inducing a voltage to produce permeabilized cells in a tissue region targeted for ablation; and An electric current is induced to produce electrolytic products to cause ablation of the permeabilized cells while maintaining the extracellular matrix of at least some of the permeabilized cells intact to allow regeneration of the tissue including the permeabilized cells.
25. The non-transitory computer readable storage medium of claim 24, wherein the induced voltage generates an electric field between 350 V / cm and 930 V / cm.
26. The non-transitory computer readable storage medium of claim 24, wherein the controller delivers 1 to 10 pulses between 100V and 1000V with a capacitance between 50μF and 100μF.
27. The non-transitory computer readable storage medium of claim 26, wherein the instructions further cause the controller to select a number of pulses based on ablation depth.
